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  97 
Abstract 98 
Background: The COVID‑19 pandemic has broadly disrupted biomedical treatment and 99 
research including non-invasive brain stimulation (NIBS). Moreover, the rapid onset of societal 100 
disruption and evolving regulatory restrictions may not have allowed for systematic planning of 101 
how clinical and research work may continue throughout the pandemic or be restarted as 102 
restrictions are abated. The urgency to provide and develop NIBS as an intervention for diverse 103 
neurological and mental health indications, and as a catalyst of fundamental brain research, is 104 
not dampened by the parallel efforts to address the most life-threatening aspects of COVID-19; 105 
rather in many cases the need for NIBS is heightened including the potential to mitigate mental 106 
health consequences related to COVID-19. 107 
Objective: To facilitate the re-establishment of access to NIBS clinical services and research 108 
operations during the current COVID-19 pandemic and possible future outbreaks, we develop 109 
and discuss a framework for balancing the importance of NIBS operations with safety 110 
considerations, while addressing the needs of all stakeholders. We focus on Transcranial 111 
Magnetic Stimulation (TMS) and low intensity transcranial Electrical Stimulation (tES) - including 112 
transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation 113 
(tACS). 114 
Methods: The present consensus paper provides guidelines and good practices for managing 115 
and reopening NIBS clinics and laboratories through the immediate and ongoing stages of 116 
COVID‑19. The document reflects the analysis of experts with domain relevant expertise 117 
spanning NIBS technology, clinical services, and basic and clinical research – with an 118 
international perspective. We outline regulatory aspects, human resources, NIBS optimization, 119 
as well as accommodations for specific demographics. 120 
Results: A model based on three phases (early COVID-19 impact, current practices, and future 121 
preparation) with an 11-step checklist (spanning removing or streamlining in-person protocols, 122 
incorporating telemedicine, and addressing COVID-19-associated adverse events) is proposed. 123 
Recommendations on implementing social distancing and sterilization of NIBS related 124 
equipment, specific considerations of COVID-19 positive populations including mental health 125 
comorbidities, as well as considerations regarding regulatory and human resource in the era of 126 
COVID-19 are outlined. We discuss COVID-19 considerations specifically for clinical (sub-127 
)populations including pediatric, stroke, addiction, and the elderly. Numerous case-examples 128 
across the world are described. 129 
Conclusion: There is an evident, and in cases urgent, need to maintain NIBS operations 130 
through the COVID-19 pandemic, including anticipating future pandemic waves and addressing 131 
effects of COVID-19 on brain and mind. The proposed robust and structured strategy aims to 132 
address the current and anticipated future challenges while maintaining scientific rigor and 133 
managing risk. 134 
 135 
Keywords: non-invasive brain stimulation, COVID-19, transcranial magnetic stimulation, 136 
transcranial direct current stimulation, transcranial alternating current stimulation, transcranial 137 
electrical stimulation 138 
  139 
1. Introduction 140 
COVID‑19 was first recognized in December 2019 and within months evolved into a global 141 
pandemic declared by the World Health Organization (WHO) in March 2020. To avert its rapid 142 
spread, country-specific restrictions have been introduced spanning strict social/physical 143 
distancing measures, stay-at-home orders and even lockdowns, workplace closings and 144 
furloughs/layoffs, postponing of elective procedures in medical centers to preserve medical 145 
resources, suspending many in-person medical consultation and clinic visits, or substituting 146 
these face to face consultations with remote interventions, e.g. telecommunications. Measures 147 
to limit person‑to‑person contact affected institutions and researchers applying non-invasive 148 
brain stimulation (NIBS) operations. With the suddenness of COVID-19 emergence, operations 149 
at clinics and research centers administering NIBS were disrupted to varied degrees - from 150 
suspension of all activities, to limiting new enrollment or abbreviation protocols, to incremental 151 
accommodations - depending on regional restrictions and the nature of underling protocols (e.g. 152 
in-person treatment vs remote treatment). The means of maintaining (and even expanding) 153 
access to NIBS during the COVID-19 pandemic are strategically evolving. Considering that 154 
NIBS is a unique non-pharmacological tool, forms of which have been successfully established 155 
for treatment of a wide range of neurological and psychiatric disorders [1-7], often on 156 
moderately or even severely impaired patients unresponsive to conventional therapies [8, 9], the 157 
reestablishment of NIBS operations in the current era of COVID-19 pandemic as well as through 158 
future epidemics is of paramount importance.  159 
 160 
Moreover, a further wave of mental health issues following this first outbreak of this virus is 161 
anticipated [10, 11]. Forms of NIBS are broadly applied and trials for mental health indications; 162 
thus, hold the potential to mitigate the psychological after-effects or comorbidities of the 163 
pandemic. This amplifies the urgent need for a roadmap of how to resume NIBS-based clinical 164 
and research activities in the face of the COVID-19 and also future pandemics. 165 
 166 
This expert consensus paper aims to outline processes that could facilitate rapid, prudent, and 167 
coordinated re-establishment of operations at institutions providing NIBS treatments or using 168 
NIBS in research. We specifically focus on low intensity transcranial electrical stimulation (tES; 169 
encompassing transcranial direct current stimulation [tDCS], transcranial alternating current 170 
stimulation [tACS], transcranial random noise stimulation [tRNS]) and transcranial magnetic 171 
stimulation (TMS). However, our recommendations may be adapted to support the 172 
reestablishment of a broad range of device-based interventions. A session of the NYC 173 
Neuromodulation 2020 Online Conference (20-22 April 2020) was dedicated to sharing 174 
experiences of NIBS researchers all over the world which inspired the plan to synthesize these 175 
opinions in the present document. Along with general guidelines and checklists, we provide an 176 
overview on the different strategies that have been introduced to mitigate the spread of the virus 177 
in NIBS procedures and NIBS laboratories. Additionally, we highlight new opportunities for NIBS 178 
regarding the current situation and discuss possible directions of research that could be taken 179 
considering the expected development of COVID-19-related diseases and disorders. The 180 
considerations presented here not only reflect the COVID‑19 crisis but also prepares the NIBS 181 
community for potential future epidemics or pandemics. 182 
 183 
In general, steps taken to support NIBS operations under any epidemic/pandemic conditions 184 
may span (a) reduction of unnecessary contact by judiciously removing protocol steps or 185 
transition to telemedicine approaches (which may include the intervention itself); (b) optimization 186 
of all at-center protocols based on sanitization (section 6.1), physical distancing (section 6.2), 187 
and streamlining procedures; (c) addition of protocols to manage risk such as COVID-19 or 188 
related symptom screening (section 6.3) or steps to support personnel affected by COVID-19 189 
medically or professionally (section 5). These overarching principles apply with varied weights to 190 
the 3 phases of COVID-19 response (section 4) and are systematized through detailed 191 
guidance (section 4, section 5, section 6, section 9), our checklist (section 3.4), case examples 192 
(section 2, section 8) and consideration for specific clinical populations (section 7). 193 
 194 
2. Results from Survey International Accommodations in Brain Stimulation Labs/Clinics 195 
to COVID-19  196 
While strategies for the use of NIBS as a unique therapeutic tool through the COVID-19 crisis 197 
are currently developing, in the immediate aftermath of COVID-19 emergency many clinical 198 
trials and experiments involving neuromodulation around the world were severely disrupted or 199 
suspended - with the exception of those that employing remote at home tDCS treatments. In 200 
many cases, research activities were diverted to writing, reviewing and analyzing data remotely. 201 
Onsite clinical services were disrupted, in some cases with services limited to teleconsultations. 202 
Following initial disruption, several on-site services began to implement remediation measures 203 
(section 8, section 9). Clinical services and trials based around remote at-home tDCS through 204 
telemedicine, were generally able to proceed with minimal accommodations (section 8, section 205 
9). This section focuses on immediate response as reflected in the survey of NIBS centers. 206 
 207 
The survey addressing the impact of the COVID-19 pandemic was sent to institutions applying 208 
NIBS (research laboratories and NIBS clinics) across the world. Replies were received from 29 209 
institutions representing 17 countries. These responses thus reflect the “situation on the ground” 210 
at the time of assessment with ongoing remediation methods addressed later in this paper. 211 
Mainly depending on the national and local restrictions in response to the COVID-19 outbreak 212 
and the nature of protocols (e.g. type of technology, trial stage, clinical population), there were 213 
substantial discrepancies in the extent to which neuromodulation operations were disrupted.  214 
 215 
In February, preclinical and clinical research activities were interrupted in China and Iran. In 216 
Europe, the restrictions imposed by governments were implemented in an uncoordinated 217 
fashion; in Italy, Portugal, Denmark and the United Kingdom and the United States, restrictions 218 
were applied to clinic services and research labs beginning in the first half of March, while in 219 
Germany, Austria and Belgium, restrictions were applied in the second half of March. 220 
Switzerland and Brazil closed their labs in mid-March. Later, between the end of March and the 221 
beginning of April, clinics and research activities were suspended and labs were closed also in 222 
Canada, Russia, India, Australia, and Japan. 223 
 224 
Globally, restrictions regarding hospitals often involved the interruption of all non-emergency 225 
services and the re-organization of routine activity focusing on handling COVID-19-related 226 
conditions. For many clinics where TMS and tES are used as treatment tools or involved in 227 
clinical research protocols, restrictions led to the suspension of non-urgent inpatient and 228 
outpatient services as well as all in-person activities. In some clinics, staff members have 229 
worked in rotation to minimize infection and provide only essential services. In Italy and the 230 
United Kingdom even home-based neuromodulation protocols were not immediately approved 231 
or feasible (Table 1).  232 
 233 
Insert Table 1 about here 234 
 235 
Examples of protocols without substantial disruption include the United States New York 236 
University (NYU) clinic and the Australia Black Dog Institute in Sydney using remote at-home 237 
tDCS treatments, which were largely able to continue operations with moderate 238 
accommodations and have even met an increased demand. Several centers providing in-patient 239 
NIBS treatment maintained at least some services, in the US including, Wake Forest (North 240 
Carolina) and Medical University of South Carolina (MUSC), to help dampen the potential surge 241 
in psychiatric symptoms and illness resulting from the pandemic. Similarly, in Belgium at Ghent 242 
University COVID-19 sub-wards were established in the psychiatric clinic for the admissions of 243 
potential infected psychiatric patients. TMS has continued to be provided in both outpatient and 244 
inpatient programs in Australia although not in research protocols. At Ghent University in 245 
Belgium, electroconvulsive therapy (ECT) has been allowed only in selected cases depending 246 
on severity. The International Society for ECT and Neurostimulation published guidance on ECT 247 
during COVID-19 [12]. 248 
 249 
With limited exceptions, the restrictions limiting the routine and non-urgent clinical services and 250 
ceasing in-person activities have severely affected clinical research. Despite the guidance 251 
offered by agencies like the Food and Drug Administration (FDA) and the European Medicines 252 
Agency (EMA) on how to manage clinical trials, clinical studies as well as single-center/multi-253 
center trials are being impacted by the COVID-19 pandemic. In the immediate aftermath of 254 
COVID-19, research labs all over the world have been instructed to limit or stop most 255 
neuromodulation research that had direct person-to-person contact and was deemed non-256 
essential. The timing of the closures varied, as well as the extent to which research was halted. 257 
Survey respondents report additional challenges arising from social/physical distancing 258 
measures, site closures, travel limitations for staff members and patients, interruption of 259 
suppliers’ delivery, and considerations if personnel or subjects might be infected with the new 260 
coronavirus. Moreover, difficulties in meeting the required protocol-procedures, including the 261 
follow-up visits and laboratory/diagnostic testing resulted in a loss of data from ongoing trials, or 262 
in a delayed data acquisition, will continue until centers fully reopen and likely beyond (Table 2). 263 
 264 
Insert Table 2 about here  265 
 266 
Based on our survey, all other institutions stopped the enrollment of new subjects. In some 267 
cases, patient treatment studies were allowed to remain open to finish currently enrolled 268 
individuals, in other cases, institutions required investigators to determine if their research 269 
studies were addressing essential need and disruption of the intervention would lead to 270 
irreparable harm. It is possible that for some studies, new participants will need to be enrolled to 271 
compensate for these losses, which was not budgeted for across grants.  272 
 273 
Even in early phases of COVID-19 responses, some centers report adapting NIBS clinical trials 274 
protocols to minimize in-person contact. Trials with remote home-based neuromodulation (tDCS 275 
and tACS) have largely continued, in some cases received updated approvals allowing for 276 
remote consenting (e-consent) and enrollment of new patients. For trials with in-center 277 
treatments, protocols are being implemented to allow for remote consenting, the remote 278 
collection of clinical data and the conduct of online cognitive tests, allowing some aspects of 279 
brain stimulation trials to continue even without home-based treatments. 280 
 281 
Respondent to the survey reported teleworking is a central component of the overall response 282 
to the COVID-19 pandemic. While a challenge to the ‘normal’ culture way of working, tele-283 
collaboration could represent an unexpected opportunity for researchers to re-analyze collected 284 
data, acquire new analysis and methods skills, design new experiments, pre-register scientific 285 
reports and brainstorm new ideas and projects. General tele-work practices and routines have 286 
also been introduced across NIBS centers to enable the remote working teams to maintain 287 
productivity, while monitoring and supporting the well-being, education, and professional 288 
development of staff (see section 5). For example, early career scientists and students 289 
concerned with the degree progress should, as appropriate, be offered additional support by 290 
adapting progress requirements (e.g. 3 months extensions concerning thesis submission 291 
deadlines) and providing them opportunities for online networking. Several respondents to our 292 
survey highlighted the opportunity to learn new skills online (through webinars, online lab 293 
meetings with guest speakers and online conferences). Responders are thus positive that the 294 
NIBS community could benefit from tele-work intellectual activities developed in the pandemic 295 
period (e.g. online conferences, papers, experimental designs, teaching materials, etc.) and the 296 
establishment of tele-communication tools should serve the NIBS community even beyond the 297 
pandemic period (e.g. project tracking and updates, new collaborations). 298 
 299 
At present, the NIBS community is in the process of preparing for a return to either partial or full 300 
operational status in the coming months. While institutional regulations for restarting in person 301 
activities will vary, institutions surveyed consistently reported implementation of personal 302 
protective equipment (PPE) standards, social distancing approaches, plans to convert the 303 
consent process and assessments to tele-/video/online administration where possible, as well 304 
as sanitization procedures. A number of labs also indicated plans for COVID-19 testing and 305 
facilities modification to improve ventilation and social distancing procedures. At present a 306 
majority of sites surveyed do not have a definitive restart date. While the future is uncertain, labs 307 
and clinics are preparing for eventual return to service with an eye toward implementation of 308 
plans to not only mitigate disruptions from the COVID-19 emergency, but also methods that will 309 
allow NIBS clinical and research services to weather future outbreaks of COVID-19 or similar 310 
events.  311 
 312 
3. Response to COVID-19 Pandemic in NIBS Labs/Clinics: Past, Current, Future  313 
A 3-phase model can describe responses to the COVID-19 pandemic in NIBS 314 
laboratories/clinics across the world, encompassing the immediate (Phase 0) to the COVID-19 315 
emergency, the current (Phase 1) state of strategic responses within evolving COVID-19 316 
restrictions (e.g. stay-at-home mandates), and planned activities (Phase 2) to optimize 317 
productivity through the COVID-19 pandemic, through potential future outbreaks, and the 318 
prolonged return to normal activities. 319 
 320 
3.1 Phase 0: Past Measures in Immediate Response to Stay-at-Home Mandates from 321 
COVID-19. 322 
In almost all cases, the rate and scale of impact from the initial COVID-19 outbreak created 323 
exigent circumstances that mandated rapid decisions. This commonly included cessation of all 324 
non-essential in-person research activities. However, institutional consideration was given in 325 
some cases for in-progress neuromodulation studies that involve the application of interventions 326 
addressing diagnoses such as depression, with some studies deemed essential and allowed to 327 
continue ongoing interventions with strict adherence to PPE for both researchers and 328 
participants. This determination was made by individual institutions with significant variability 329 
across sites. In response to stay-at-home mandates, entire study teams were faced with moving 330 
all activities to remote/tele continuation. For those involved in studies deemed “essential,” 331 
structured plans to allow study team members in labs/clinics and access to appropriate PPE 332 
were required. In addition, studies either already designed for remote administration of 333 
assessments and/or interventions were allowed to continue, with either minor or no modification 334 
to existing protocols.  335 
 336 
In some cases, studies were able to modify their existing protocols to continue research efforts 337 
on a fully remote basis using tele-/online/video assessments or at-home brain stimulation 338 
procedures. However, many studies are incompatible with remote continuation and were 339 
required to stop. For those faced with remote/telework, documentation, reports of activity, 340 
approvals, updates, online audits, online analysis, dissemination of results through manuscript 341 
development, online conferences and study team virtual meetings represented transitions 342 
requiring minimal effort to implement. However, for those requiring access to specialized 343 
hardware, specially protected data, or software, as a few examples, housed within the 344 
workplace, this transition either proved difficult or resulted in work stoppage. Regardless, an 345 
important element of the initial and ongoing response to COVID-19 across ongoing studies 346 
involved communication with all participants currently enrolled in ongoing studies to provide 347 
information regarding how their participation in the study would be impacted by stay-at-home 348 
mandates, as well as providing additional information for available local resources to address 349 
potential concerns for their welfare and well-being during the outbreak (e.g. tele-mental health 350 
services, community assistance programs, etc.).  351 
 352 
3.2 Phase 1: Current Response. 353 
During the COVID-19-related stay-at-home mandate, critical consideration must be given to re-354 
integration strategies and approaches for restarting studies and trials. The timing and details of 355 
re-integration procedures will vary significantly across institutions, as did study stoppage and 356 
stay-at-home procedures. Nonetheless, brain stimulation teams can begin planning for potential 357 
iterations of re-integration procedures. At present, commonly discussed strategies across 358 
institutions include a tiered return to institutions for study teams, potential split shifts for study 359 
team members to cover study activities, PPE for all participants and study staff, COVID-19 360 
infection or antibody testing procedures, body temperature assessment of all staff and 361 
participants, redesign of lab procedures/space to minimize person-to-person contact, new 362 
facility and equipment sanitization procedures, among others (see also below, section 6). While 363 
institutional procedures will vary, advanced planning for how these procedures will impact study 364 
continuation is important. In addition, study teams will be faced with a backlog of participants 365 
that either missed planned follow-up visits or have upcoming follow-up visits, as well as a need 366 
to replace participants whose intervention schedules were interrupted by stay-at-home 367 
mandates. Study teams will likely be strained to perform all needed activities for study 368 
continuation upon return. Advanced planning for prioritization of study activities will be important 369 
for efficient transition back to in-person activity.  370 
 371 
3.3 Phase 2: Future Response to COVID-19 and Subsequent Outbreaks. 372 
We are also faced with the uncertain possibility of one or more recurrent waves of COVID-19 373 
and similar epidemic/pandemic outbreaks in the coming months and years. Thus, careful 374 
consideration of protective equipment to protect research participants and staff members, to 375 
disinfect tools and labs, and long-term planning for implementation of remote assessment 376 
and/or intervention procedures may prove critical for long-term continuation of studies should 377 
this become a reality. Further still, once rapid COVID-19 testing and antibody assays are proven 378 
to be reliable and widely available, we will have tools that may allow us to alter how we respond 379 
to future waves of COVID-19. If procedures for maximizing the safety of in-person study 380 
activities (modification of space for face to face visits, restructuring of waiting areas to separate 381 
participants/patients, stringent PPE procedures, etc.) can be implemented immediately following 382 
the current outbreak, these methods paired with new COVID-19 testing procedures may 383 
redefine how we respond to future COVID-19 pandemic events. For example, most TMS clinics 384 
around the world were shut down for depression treatment following the initial COVID-19 385 
outbreak, preventing access to care needed by patients. If careful in our current and future 386 
response, different approaches for safely continuing such activities may be possible. We can 387 
consider developing institution specific standard operating procedures for the labs and 388 
orientation of all staff members to deal with future outbreaks. As such, we provide a summary of 389 
important considerations for response to COVID-19 as well as a checklist for adapting research 390 
and treatment practices to COVID-19 in Table 3.  391 
 392 
Insert Table 3 about here 393 
 394 
3.4 Recommendations (Checklist) for Adapting Research and Treatment Practices to 395 
COVID-19 396 
Here we provide a list of recommendations for adapting research and treatment practices to 397 
COVID-19 pandemic. 398 
 399 
1) Conduct a systematic updated risk-benefit analysis of each protocol to decide for 400 
each effort if it should continue and inform remaining steps; this may include 401 
contingency plans to changes in a given circumstance (e.g. if X happens the trial will 402 
need to wind down under these conditions), engaging all stakeholders in discussion 403 
(e.g. staff, program office, DSMB, etc.), and statistical consultation with respect to the 404 
power to make conclusions regarding protocol changes (e.g. change in dose, trials 405 
terminated prematurely) and associated changes in outcome reporting (e.g. feasibility 406 
instead of efficacy). 407 
 408 
2) Transition as many study procedures as possible to electronic or video format (e.g. 409 
consent process, screening visit, assessment tools, switch to an established home-410 
based techniques). 411 
 412 
3) Remove non-essential steps in protocols that require in-person interactions.  413 
 414 
4) Establish stringent safety and sanitization procedures for all required in-person 415 
interactions and train staff in execution of these procedures (with documentation of 416 
training completion). Ultimately, staff will have to follow regulatory and protection 417 
procedures adopted by specific research or clinical settings (e.g. nursing home 418 
setting) will have to follow COVID-19measures for that setting; or in-person visit at a 419 
patient’s home will require compliance with COVID-19protection mandated for home 420 
care. Therefore, developing and updating protocol specific safety procedures requires 421 
research staff communication and coordination with institutional (clinical) leadership 422 
for the specific setting in which NIBS studies will be carried out.  423 
 424 
5) Implement all institution required safety procedures (e.g. screening, PPE, COVID-425 
19testing, etc.). Develop study-specific considerations for staff who recovered 426 
COVID-19. 427 
 428 
6) Consider changes in intervention that do not impact trial integrity (e.g. number of 429 
visits, inclusion/exclusion) or consider changes that strategically change trial scope 430 
(i.e. still allow for meaningful publishable outcomes; e.g. changing to a pilot trial). 431 
 432 
7) For in-person protocols, streamline the entire process from participant preparing to 433 
leave their home, to transportation, to arriving at clinic/lab, to leaving the clinic/lab to 434 
maximize social/physical distancing (including between patients and between staff) 435 
with special attention to neuromodulation steps; where possible, the clinical trial may 436 
provide support for car service for participants to avoid public transportation. 437 
 438 
8) Add additional telemedicine steps (follow-ups) to adjust for changes in protocol; Add 439 
steps responsive to COVID-19 related concerns. This can include additional data 440 
collection that may impact immediate decisions (vii) or later analysis such as testing 441 
all subject temperature or surveying for COVID-19 related symptoms. Determine 442 
protocol for identified COVID-19 positive patients, including if they are not critically ill 443 
or without symptoms. 444 
 445 
9) Review explicit protocols / consideration for adverse events (related or not to the 446 
intervention) so that the decision tree (what to do, who makes the call, what needs to 447 
be reported) is mapped out beforehand (patient or caregiver has X symptoms leading 448 
to Y actions). 449 
 450 
10) Obtain IRB approval for any applicable changes (e.g. all the above) in protocol 451 
including patient consent in regard to any new anticipated risks. 452 
 453 
11) Take steps to share your plans, lessons, learned, and ongoing experiences with the 454 
broader community. Survey all stakeholders (e.g. building facilities, research 455 
personnel) to gauge comfort with planned activities. 456 
 457 
4. Regulatory Factors  458 
4.1 Trial Registry (e.g. ClinicalTrials.gov) Report Updating 459 
All clinical trials registered with a database such as ClinicalTrials.gov should be appropriately 460 
updated to reflect the mitigation plan to limit risk of infection, a revised timeline for enrollment 461 
and any social/physical-distancing related adaptations to the protocol. Participants may be more 462 
willing to enroll knowing that precautions have been made.  463 
 464 
4.2 Institutional Review Board/Ethics Review Board Approval 465 
Some ethics boards may mandate withholding research recruitment for some period at peak of 466 
outbreaks. While pausing a study does not necessarily require notification to the IRB/Ethics 467 
Board, any protocol changes to the process of interaction, intervention or assessment of 468 
participants must be reviewed and approved by the resident ethics board. This includes but is 469 
not limited to modifications of the method of administration from in person to online, shifts to at-470 
home neuromodulation procedures, change in participant payment method, etc. Study sponsors 471 
may have differing timelines for study restart than local institutions and ethics boards.  472 
 473 
4.3 Converting to a Video/Online Consent Process 474 
Many research groups are now converting their consent and screening visits to a tele-475 
health/video-visit. The term most frequently used is “e-consent or e-consenting”. The 476 
requirements for this vary by Institutional Review Board, but all contain the core features of 477 
providing the prospective participant with a copy of the Consent (e.g. via mail or email), going 478 
over the Consent remotely, and obtaining a signed copy of the Consent (e.g. mail or email) 479 
which the investigator countersigns on the date of receipt. Once the participant signs the 480 
consent, typically with either video observation or through a secure online signature process, 481 
this enables the investigator to proceed with the screening visit, which can be facilitated using 482 
electronic forms (e.g. RedCap, Qualtrics, ClinCapture). Such video/online consents and 483 
video/online-based screening visits lessen the risk of contracting the illness for everyone, and 484 
may provide a more effective means of performing a Consent visit involving all necessary safety 485 
precautions (masks, disinfection, etc.). 486 
 487 
4.4 Communication with Funding Agencies and Data Safety Monitoring Boards 488 
Study suspension and any revisions to procedures within funded studies should be discussed 489 
with the funding agency. In addition, for clinical trials with a standing data safety monitoring 490 
board (DSMB), study suspension and restart as well as changes in study procedures should be 491 
forwarded to the DSMB for approval.  492 
 493 
4.4 Extensions of Funding for Research 494 
In most places across the world, neuromodulation studies have been suspended, yet the costs 495 
associated with those experiments (e.g. salaries, animal housing and food costs) have 496 
continued. This placed a financial burden on these studies and will also delay the final results of 497 
the studies. Thankfully, several funding agencies, including the US National Institute of Health, 498 
Wellcome Trust and the Medical Research Council UK, and Swiss National Science Foundation 499 
have announced the ability to apply for an Administrative or grant Supplement to cover 500 
unforeseen COVID-19-related costs. They have also streamlined the process for getting 501 
approval for a No Cost Extension. These steps offer significant relief to researchers and 502 
increase the likelihood that the dedicated resources already invested in these projects will be 503 
fruitful.  504 
 505 
5. Human Resources Considerations  506 
Supporting our colleagues, particularly Early Career Researchers, is vital in this time of crisis. 507 
There are a number of issues that this period brings; here we will discuss some of the most 508 
pressing. This cannot be an exhaustive list, however, and it is vital that as a field we are 509 
sensitive to the additional needs of our colleagues. It is perhaps important to note that we are in 510 
no way encouraging a decrease in the standards required for publication. Rather, an increase in 511 
understanding around the circumstances in which that work is done is called for.  512 
  513 
Firstly, it is vital to recognize the additional anxiety the current situation will place on Early 514 
Career Researchers and PhD students. For students with only months of funding left with which 515 
to complete their degrees, this is a very stressful time, as it is for those more senior researchers 516 
with grant deadlines. It is to be hoped that this paper will provide helpful suggestions and 517 
contribute to the discussion for ways to ease the difficulties faced at this time, however, the 518 
inevitable anxieties associated with the current situation are real and should be explicitly 519 
acknowledged. We must work to address these and to support our colleagues through this 520 
difficult time. 521 
  522 
Research groups around the world will be physically separate, indeed often spread across time 523 
zones if students choose to spend this unprecedented period at home. This will inevitably lead 524 
to psychological stress, something that has already been seen in China [13]. Maintaining group 525 
cohesion is vital and implementing explicit support structures is necessary, particularly for those 526 
isolating on their own with families elsewhere [14]. While online tools cannot replace face-to-527 
face interactions, they are vital substitutes in current times. The vast majority of labs will have 528 
moved work meetings online already, but in addition to these it is important to recognize that for 529 
many work is also a social experience and now more than ever, an essential source of support. 530 
Scheduled coffee breaks, games nights, film nights, cocktail hours (with alcoholic or non-531 
alcoholic drink of choice) and many other social events are all being implemented successfully 532 
across the world to create at least some of the social interactions so important to both our 533 
mental wellbeing and our lab cohesion. Explicitly matching group members in a buddy-scheme, 534 
where each lab member has a partner that they have to contact even briefly each day, is a way 535 
of providing a light touch method to flag potential mental health issues early. While we cannot 536 
prevent the inevitable increased rates of mental health problems in our community, making sure 537 
that we explicitly discuss the difficulties we all face in this pandemic, and the inevitable mental 538 
health repercussions, will hopefully allow those facing particular problems to speak out and 539 
receive the support they need [15].  540 
  541 
It is necessary to act now to ensure that the current pandemic does not have long-lasting 542 
negative consequences on the field. NIBS has historically had a lack of female representation 543 
[16], something that leaders in the field have made a concerted effort to address in recent years 544 
[17] with increasing success. However, the current crisis is likely to exacerbate the gap between 545 
women and men, and between carers and non-carers, in terms of available time and 546 
opportunities. The burden of care and responsibilities have fallen unequally in this crisis - for 547 
some this is a virtually unheard of period of quiet in which they have the time to produce as 548 
much, if not more, work than normal. However, for the field as a whole it is vital to recognize that 549 
for others this is a time where demands and anxieties have increased, and available time has 550 
shrunk considerably. The “room of one’s own in which to write” [18] is for some a daily reality 551 
and for others merely a distant dream. The real effects of this inequality across academia is 552 
already being spoken about anecdotally by editors, who report decreases in the number of 553 
submissions from women [19] and, possibly, increases in the number of submissions from men. 554 
How those trends continue will need to be carefully monitored. 555 
  556 
While it is extremely difficult to judge what effect other responsibilities may have on our 557 
colleague’s productivity, it is timely to recognize that although individual circumstances vary 558 
substantially on average women still carry the majority of the burden of both caring 559 
responsibilities and household tasks even when both partners work [20] - something that can at 560 
the moment only exacerbate gender imbalances in the field. It must therefore, be the 561 
responsibility of all of us, particularly those in more senior positions, to acknowledge this and to 562 
challenge the potential prejudices of others and ourselves when making career-determining 563 
decisions, not just at the moment but in the months and years to come. Suggestions have 564 
already been made as to ways to tackle this, including explicitly treating this period as carers 565 
leave in future applications [21]. 566 
  567 
In the shorter term, the social/physical distancing measures in place around the world are not 568 
only limiting what we can do in terms of science, but limiting the opportunities for all of us, 569 
particularly the Early Career Researchers, to network and to meet potential advisors for the next 570 
stage of their careers. Initiatives such as on-line conferences are likely going to be the 571 
mechanism for sharing our science for at least the next few months and provide an essential 572 
opportunity for our ECRs to discuss their work. However, what is difficult to reproduce on-line is 573 
the informal chat over coffee with others in the field, which can often provide the start to a 574 
conversation that ends with a postdoctoral position or support for tenure-track applications.  575 
  576 
Overcoming these restrictions will be difficult: by definition it is challenging to formally engineer 577 
informal discussions. We all have a responsibility to recognize this, and to be responsive to 578 
unsolicited emails from researchers elsewhere. This is also a time to embrace the ability to 579 
invite speakers from around the world to give informal talks at lab meetings and small 580 
gatherings without the costs involved in travel. Not only does this broaden our horizons at a time 581 
when it is all too easy to reduce our interactions, it also has secondary benefits. Small lab talks 582 
provide excellent opportunity to interact with external researchers in a small group. Inviting 583 
senior researchers to speak can provide a route into discussions for ECRs, inviting ECRs to 584 
speak provides valuable experience for them.  585 
  586 
In practical terms, many universities have relaxed the timescales required for PhD students, 587 
something that we must support and petition for. Many grant bodies around the world have 588 
already announced blanket extensions to current funding - as a field it is our responsibility to 589 
make these allowances as equitable as possible. A number of routes through the current crisis 590 
have been suggested in the rest of this article which will allow us to continue our research with 591 
disruption kept to a minimum. However, in the inevitable rush back to the lab, for the long-term 592 
sake of the field we must not forget to bring everyone with us. 593 
  594 
6. General Guidance in Reopening Labs/Clinics  595 
As with all COVID-19 safety procedures, regional and institutional guidances, applied judiciously 596 
to specific protocols considering changing conditions, will determine which procedures should 597 
be implemented and which can be abbreviated. Our recommendations below explain a range of 598 
existing procedures in the context of NIBS application and should not be considered necessary 599 
or sufficient for every situation. 600 
 601 
6.1 Social/Physical Distancing Protocols 602 
A critical factor in controlling and reducing the spread of SARS-CoV-2 and the associated 603 
COVID-19 has been so-called social/physical distancing, which means preventing physical 604 
contact especially of persons who otherwise would not have social contact. What is essential to 605 
understand here is that the terminology “social/physical distancing” may be somewhat 606 
misleading, as what matters in essence is the physical distancing. The latter in turn has mainly 607 
been recommended because one dominant way by which SARS-CoV-2 is transmitted is by 608 
airborne droplet infection. More specifically, aerosols emanating from the upper respiratory 609 
pathway housing the virus in high concentrations are thought to passively “travel” through the air 610 
and remain airborne for some time. While the exact travel distance and the amount of time that 611 
infectious materials maintain in the air are currently a matter of debate, most recommendations 612 
suggest keeping (at least) 2 m (6 ft) distance to any other person and assuming that any 613 
unknown person could potentially be infectious [22]. Minimizing duration of contact is another 614 
strategy that may be considered based on study protocols, current federal and institutional 615 
guidances, and current scientific consensus on impact of briefer contact times (protocols) in 616 
reducing risk to operators and patients. 617 
 618 
Social/Physical distancing parameters as defined by governments and regulatory authorities 619 
vary among countries, states and counties and change over time as a regional Covid-19 620 
situation develops. The following procedures are therefore region and institute specific, and 621 
subject to ongoing risk-burden evaluation. As applicable, social distancing should be maintained 622 
in all offices. The allowed density of staff in given rooms should be considered along with the 623 
need for and mechanism of minimizing face-to-face interaction (e.g. by using chat, emails or 624 
telephones). As applicable to the specific time and protocol, it may be prudent to wear masks 625 
and maintain a recommended interpersonal distance. If and when patients should wear masks 626 
for necessary clinical treatments should be determined. For studies and therapies where 627 
wearing masks hinders the efficacy, transparent face masks could be considered.  628 
During NIBS procedures, it is often not possible to maintain the recommended physical 629 
distance, at least for some amount of time. For instance, applying electrodes for tES or 630 
adjusting the position of TMS coils requires direct contact between the person applying NIBS 631 
and the person receiving NIBS. Robotic TMS provides some opportunity for TMS administration 632 
with operators further removed from participants (easily by 2 meters/ 6 feet except for brief 633 
localization to navigation, though the participant can be trained to do this). However, such 634 
devices will not be available to all labs and clinics. In these instances, protective measures are 635 
important to reduce the inhalation and expiration of aerosols, and the amount of time, during 636 
which the recommended physical distance cannot be complied with, should be restricted to a 637 
minimum possible.  638 
 639 
6.2 Personal Protective Equipment (PPE) 640 
PPE can take many forms such as wearing face masks that should cover both mouth and nose. 641 
There are different safety standards for these masks, and we recommend that medical and 642 
research personnel in constant contact with potentially infected persons (including participants 643 
and patients, but also co-workers) wear those with the highest safety standards (e.g. N95 644 
masks). Importantly, the masks should be regularly changed (with maximal wear time differing 645 
as per the specific type and make of the mask) as otherwise they might even be 646 
counterproductive due to the accumulation of viral material at the inner side of the mask. If 647 
appropriate, patients and participants may be provided with single use or disinfected multiple 648 
use masks by the neuromodulation labs. 649 
 650 
As appropriate, in addition to masks, medical and research personnel may consider wearing 651 
transparent visors, or protective eye wear covering the upper parts of the face and especially 652 
the eyes, through which viral material can also easily enter the organism. Visors that cover the 653 
whole front of the face extending way down below the chin may supplement face masks for 654 
researchers and participants. In theory, the appeal of visors without masks is allowing better 655 
verbal communication, compared to face masks, which limit articulation and comprehensibility of 656 
speech sounds i.e., the “muffling” effect- b but such considerations are secondary to safety. The 657 
appropriateness of visors and other PPE (e.g. goggles, protective coats) in various social and 658 
clinical environments will ultimately depend on current regional and institutional guidances. In 659 
some regions and institutions, current recommendations are to use both a surgical mask and 660 
visor for direct interactions with patients. 661 
 662 
Moreover, medical and research personnel should wear single use gloves when touching 663 
participants and patients, and the latter may also want to be provided with such gloves when 664 
touching apparel that will be touched by others, such as input devices, computer keyboards, 665 
desks, etc. 666 
 667 
6.3 Facilities and Sanitization Procedures 668 
As with all COVID-19 safety procedures, regional and institutional guidances, applied judiciously 669 
to specific protocols considering changing conditions, will determine which procedures should 670 
be implemented and which can be abbreviated. Our recommendations here thus index possible 671 
applicable procedures. 672 
 673 
Besides body-worn protective measures, room dividers and transparent shields can be 674 
considered for installation in facilities that are not already designed for one-on-one visits. These 675 
devices constitute a physical barrier protecting spread of aerosols throughout the room from 676 
participants and patients to personnel and will be especially important at patient receptions. 677 
Provisions of hand washing opportunities, or hand sanitizers for patients and participants at the 678 
entrance to research and treatment premises are also generally recommended, and they should 679 
be provided in a way that they can be regularly and easily used by medical and research 680 
personnel, after each new contact with a new person. Additional measures to minimize airborne 681 
particles being transmitted are regular ventilation of research and treatment laboratories, regular 682 
disinfection of surfaces, such as doorknobs, apparel, furniture, research equipment and visors 683 
as well as shields, ideally after each use by a new person, is highly recommended. Within 684 
elevators, covering all buttons with plastic membranes that are changed daily is advised. Tissue 685 
paper or small wooden pieces can be provided to push the button without skin contact.  686 
 687 
Special consideration should be given for employing single-use equipment when possible. For 688 
example, within tES, a variety of single-use and multi-use electrodes is available. Maximizing 689 
the use of single-use devices that contact the participant/patient serves to minimize potential 690 
translocation of virally active material from one participant to the other. Where devices must be 691 
used across participants, antibacterial disinfection may not be sufficient. In all cases, all 692 
research equipment should be sanitized/disinfected before and after use. In this, special 693 
consideration as to which type of disinfectant is used needs to be applied, as the functionality of 694 
some electrodes may be negatively affected when disinfected with alcohol-based disinfectants. 695 
One potential alternative to alcohol-based disinfectants is the use of Hydrogen Peroxide. We 696 
recommend referring to manufacturer information to evaluate possible disinfection routines. All 697 
disposable supplies should be discarded in appropriate bio-waste repositories. Note that most of 698 
the considerations regarding sanitization protocols should not only be applied to laboratories 699 
and treatment facilities, but also for the off-site home use mentioned above in this paper. 700 
The following disinfection and sanitization protocols are aiming to give research facilities some 701 
flexibility to re-start NIBS clinical services and research operations during the current COVID-19 702 
pandemic and possibly similar outbreaks in the future for patients with non-COVID-19 needs or 703 
complex chronic disease management requirements. 704 
● After the NIBS session is over, the environmental surfaces in the stimulation 705 
room should be sanitized using a 1% Hypochlorite solution, with a disposable 706 
antiseptic cloth [23]. Also, all the stimulation equipment, including magnetic coil 707 
(for TMS) stimulator, electrode/stimulator cables, EEG cap, tape measure, 708 
electrodes and sponge pockets should be sanitized. Follow manufacturer specific 709 
guidance on how to clean the stimulator. Furthermore, it is prudent to check for 710 
any leaked fluids from the participant on the stimulation chair. 711 
● The stimulator trolley and treatment chair should be wiped with a permitted 712 
cleaning product (normally bacillocid is allowed, but it is better to check with the 713 
manufacturer). 714 
● If an MRI/MEG‐compatible stimulator is available for concurrent application of 715 
NIBS during the recording of neuroimaging or electrophysiological data, then the 716 
gantry and the RF coil should be sanitized with a permitted cleaning product. The 717 
MRI table also should be sanitized with any of the approved products. The coils 718 
need to be disinfected once again after the scanner room is thoroughly sanitized, 719 
then the next patient or participant may be taken [24]. It is necessary to ensure 720 
that the metal nose piece of surgical masks, if applicable, is not ferromagnetic 721 
[25]. 722 
 723 
6.4 Vulnerable Populations 724 
An additional aspect that requires consideration is the inclusion of individuals that belong to 725 
high(er) risks groups, both on the side of the personnel and the research participants or 726 
patients. Currently, older age, a history of cardiovascular diseases and diseases affecting the 727 
respiratory system (e.g. asthma, smoking), but also diabetes, obesity and cancer or other 728 
diseases affecting the immune system directly or through immuno-depressant treatment (e.g. 729 
multiple sclerosis [MS]) are widely considered as major risk factors (see e.g. [26], for a meta-730 
analysis). However, what constitutes a major risk to develop COVID-19 is still not definitely 731 
established scarce, and we thus recommend to closely monitor the accumulating scientific 732 
evidence in this respect (e.g. via [27]). For now, we recommend that individuals belonging to the 733 
groups mentioned, as well as individuals being in close regular contact with individuals 734 
belonging to such groups, should only enter studies or be treated under special circumstances 735 
and with utmost care. 736 
 737 
A logbook of each lab and treatment room should be maintained, listing personal interactions 738 
that took place so that in case of an infection, all persons in contact with the infected person can 739 
be traced back and informed about a possible infection. In such cases, we strongly recommend 740 
swift reactions, including quarantining of the potential new carriers, exclusion from work 741 
premises, and rapid testing for SARS-CoV-2. 742 
 743 
On a critical note, many of these measures are not based on concrete evidence on their 744 
effectiveness. There is still insufficient knowledge about which of them are necessary and 745 
sufficient to prevent further spread of the virus. However, to the best of our current knowledge, 746 
they can be expressed as strongly recommended. Another critical aspect is whether the 747 
measures can be implemented consistently. In many countries, for instance, masks but even 748 
disinfectants are still not available in the required quantities and using the limited number of 749 
protective measures for protection of healthcare workers treating COVID-19 patients should be 750 
given higher priority than using it for neuromodulation research. 751 
 752 
6.5 Personnel, Participant and Patient Screening  753 
Additional precautions are regular (self-)screening by personnel, patients and participants, for 754 
potential infections or contact with infected persons. This can be achieved by a symptoms 755 
checklist, which every person entering the research or treatment premises has to provide, as 756 
well as by temperature measurements at the entrance to the research facilities. All of the latter, 757 
however, may be of limited validity, as many persons infected by SARS-CoV-2 have been 758 
reported to be asymptomatic, and do not develop the associated disease (and thus will neither 759 
show symptoms, including fever). Many institutions have plans to implement either rapid 760 
COVID-19 testing and/or COVID-19antibody testing of faculty and staff prior to reentry into the 761 
workplace. In addition, some institutions are considering requiring all study participants to 762 
undergo rapid COVID-19 testing prior to in person study activity. Availability and implementation 763 
of these tests will vary across institutions.  764 
 765 
The scientific basis for SARS-CoV-2-related immunity and reliability of antibody testing remains 766 
under development. Subject to ongoing scientific insight and respecting regional and 767 
institutional guidance, screening for antibodies in the blood of staff or participants could be one 768 
element supporting the basis for an “immunity passport” or “risk-free certificate” that would 769 
enable individuals to return to work or research assuming that they are protected against re-770 
infection. In this respect it should be noted though that a previous infection and the development 771 
of immunity may not protect against another episode of infection, and development of the 772 
disease (see e.g. [28]). However, whether the immunity passport policy will apply systematically 773 
or not, there is value in specific protocols and based on broader COVID-19 situation factors in 774 
applying such tests during recruitment procedures to improve patient-clinician safety or trial 775 
integrity. 776 
 777 
7. Specific Clinical Populations 778 
7.1 Stroke Patients: Stroke survivors can experience a wide range of impairments and 779 
disabilities including motor deficits and the loss of ability to produce and/or to understand 780 
language (aphasia). Among other treatments, use of neuromodulation techniques has been 781 
proposed to enhance/facilitate stroke-recovery. Past studies have integrated centrally acting 782 
tDCS with peripherally acting intensive motor or language rehabilitation protocols [29-37]. 783 
Before COVID-19, there were several tDCS aphasia treatment protocols published with positive 784 
outcomes [38] but during the first half of March, the pandemic forced most of the labs involved 785 
in NIBS and stroke recovery to suspend clinical and research activities. COVID-19 has 786 
significantly increased the risk of social isolation and associated depression in people with 787 
aphasia. Indeed, language and cognitive problems limit the use of digital media (i.e. cellular 788 
and/or social network) to maintain social contact. Patients with motor symptoms have also been 789 
penalized as a result of COVID-19 since it might be more difficult for them to move or get 790 
around with limited caregiver and physical or occupational therapy support. Stroke patients 791 
being in an older age category increase the risk of contracting the virus and potentially having a 792 
worse outcome; thus, in order to contain the exposure, they will probably be forced to stay-at-793 
home for a longer period than young people augmenting the possibility of psychological distress 794 
and depression. To address these mental health issues, researchers from the Aphasia research 795 
Lab at the IRCCS Santa Lucia Foundation in Rome have launched an online interview in the 796 
aphasic population to evaluate whether anxiety and fear towards COVID-19 contagion would 797 
discourage the restart of rehabilitation. One concern is that patients worried about COVID-19 798 
may be deprioritizing their neurorehabilitation needs and may develop an attitude of resistance 799 
towards clinical research, deemed non-essential.  800 
Assuming that regulatory agencies and medical centers will hopefully lift the research and 801 
clinical treatment suspensions in the coming months when appropriate mitigations plans are in 802 
place, it is important to consider that tDCS protocols for motor and/or aphasia rehabilitation will 803 
be hampered by the difficulty in maintaining an adequate safety distance during electrodes 804 
application and even more importantly by the mandatory use of masks. Indeed, for language 805 
and cognitive interventions, it is extremely important that both the therapist and the patient 806 
understand each other, being able to see their mouth’s movements (i.e. ‘lip-reading’ is known to 807 
facilitate communication). Transparent face shields without masks might be a good alternative 808 
option here. However, these will not resolve the question of electrode application while keeping 809 
a safety distance. Another possibility is to develop remote, but supervised and controlled 810 
interventions at the patient’s home using home-based tDCS devices. As appealing as this 811 
sounds, considering that most patients have cognitive and physical limitations in applying the 812 
‘kit’ and that NIBS approaches require a peripheral intervention (e.g. traditional speech therapy 813 
or physical-occupational therapies), it will be challenging to provide these combined approaches 814 
in a patient home. For stroke patients, there might be also an option to develop remote 815 
intervention in an outpatient clinical setting ensuring that there is enough separation and 816 
physical distance between the patient and the investigators. There is no doubt that requests will 817 
be made to regulatory agencies to allow for clinical research in stroke recovery to be conducted 818 
in a remote way or at the patient’s home by integrating tDCS with other telerehabilitation 819 
techniques and digital interventions e.g. computer delivered rehabilitation. In this way, we may 820 
resolve the issue related to language distortion due to wearing a cover that, masking not only 821 
verbal communication but also facial expressions, would anyway hinder communication 822 
exchanges. Moreover, since some tDCS language protocols have already been validated, we 823 
might think of offering caps to the patient’s family with the position of the electrodes already 824 
fixed to facilitate and standardized application. However, we must be mindful that by doing so 825 
we may be limiting the breath of patients we can study and the generalisability of our findings 826 
e.g. only those who have prior experience using digital technologies, with limited cognitive 827 
difficulties, who have family members that can monitor and assist putting on the ‘home-kits 828 
would benefit from those treatments. We also have to consider the safety of the remote tDCS 829 
protocols. Patients might be at a risk of seizures after stroke and fatigue is an important factor 830 
which might interfere. So timing and careful monitoring of the remote interventions are additional 831 
variables to take into account. Considering past remote neuromodulation studies and current 832 
COVID-19-related problems, tDCS protocols either at home or in a remote location at a medical 833 
center (separating the patient from the clinician) may be an opportunity as well as a challenge in 834 
the future. 835 
 836 
7.2 Pediatric Research: For over the last decade, neuromodulation has been safely integrated 837 
in pediatrics with myriad diagnoses and disorders and promising outcomes [39, 40]. 838 
Protocols have integrated TMS, rTMS, tDCS and theta-burst in varying age ranges from 839 
infancy through young adulthood. Although commenced in adult populations, pediatric tele-840 
neuromodulation protocols have not yet been established. In response to COVID-19, the 841 
Pediatric Neuromodulation Laboratory in the Medical School at the University of Minnesota, 842 
in conjunction with physicians from Gillette Children’s Specialty Healthcare, and Mayo-843 
Rochester, have developed an online survey investigating the impact of COVID-19 and the 844 
stay-at-home mandate on family/child access to rehabilitation care for children with cerebral 845 
palsy. Pediatric Investigators in our Department of Psychiatry are also integrating our 846 
protocol to run a parallel survey, for families of children with related psychiatric diagnoses. 847 
We are now commencing a novel pediatric telehealth NIBS study investigating tDCS in the 848 
home setting via remote/telehealth specifically for children with perinatal stroke and resultant 849 
cerebral palsy. This study is informed by our previous adult stroke neuromodulation 850 
telehealth studies, and previous established guidelines. The first phase of this study will 851 
investigate the feasibility and reliability of parents/caregivers in operating the device and 852 
positioning the electrodes. Phases thereafter will establish child tolerance and safety, along 853 
with administration and assessment of stimulation in conjunction with rehabilitation 854 
interventions. 855 
 856 
7.3 Patients with Chronic Neurological Conditions: Neuromodulation is an appealing option 857 
for symptom management and rehabilitation for those living with chronic neurological conditions 858 
such as multiple sclerosis, Parkinson’s disease (PD) and other disorders with cognitive or 859 
movement dysfunctions, with many positive signals from the literature and large controlled trials 860 
underway. Specific considerations with these patients include potential cognitive impairments, 861 
which may reduce the ability to understand and complete the required study procedures, as well 862 
as sufficient motor functioning to operate any study equipment from a remote (home) location. 863 
However, in our work to date, we have found that the majority of those living with MS, ages 18 864 
to 80 years and with varying disability levels including wheelchair dependency and impaired 865 
upper limb motor functions, can complete our remotely supervised protocol with guidance from 866 
a tDCS technician and can also include caregiver training for support. It is important to include 867 
these patients with more advanced disease for full representation of the disease spectrum 868 
because they often have fewer treatment and rehabilitative options. Continuity of care for 869 
patients in research or clinical protocols is important, and ongoing communications serve as a 870 
connection to the clinic for those patients with stable disease who otherwise would not be in 871 
contact with their treatment teams during the current time period. 872 
 873 
7.4 Addiction: The secondary effects of the COVID-19 pandemic (e.g. periods of lockdowns, 874 
closures of routine clinical services and forced self-isolation deriving) have uniquely 875 
challenged the health and welfare of people vulnerable to drug and alcohol addiction as well 876 
as those with behavioral addictions (gambling, gaming, compulsive eating, Internet and new 877 
technologies). Inpatient or residential treatments have been interrupted since the substantial 878 
risk of coronavirus spread with congregation of individuals in a limited space. Alcohol and 879 
marijuana sales have also increased as, in many areas of the world, businesses that 880 
dispense/sell these products have been some of the few businesses to remain open as they 881 
are often deemed essential services. This suggests a burgeoning wave of drug and alcohol 882 
related problems will emerge in society, and highlights the need to return to delivery of 883 
clinical treatment research in this area. That said, a recent summary by the National Institute 884 
of Drug Abuse highlighted original research demonstrating that chronic smokers and opiate 885 
users are likely at higher risk for COVID-19 related morbidity associated with respiratory 886 
disease [41]. Data from the Chinese Center for Disease Control and Prevention have 887 
suggested that COVID-19 has an increased fatality in patients with chronic conditions, like 888 
respiratory and cardiovascular diseases [42]. An international group of experts on addiction 889 
medicine, infectious diseases, and disaster psychiatry has recently explored the possible 890 
raised concerns and nicely provided recommendations to a comprehensive healthcare 891 
response to COVID-19 in SUD [2]. To deal with the consequences of the COVID-19 on 892 
addictions, efforts will require joining partnerships and possibly unprecedented use of 893 
technology in which neuromodulation by NIBS would nicely fit, especially thinking in 894 
distance treatment with an online monitoring system.  895 
 896 
7.5 Older Adults: It has become clear that older adults have the highest rates of morbidity and 897 
mortality associated with COVID-19. Consequently, older adults represent a vulnerable 898 
population and careful consideration should be made when bringing them into a research or 899 
clinical environment wherein they may be exposed to others that are infectious. Special 900 
consideration should be given in regard to lab/clinic activities with older adults that have 901 
comorbidities that further increase risk for poor COVID-19 outcomes, such as chronic 902 
obstructive pulmonary disease. While standard PPE, sanitization and minimization of 903 
person-to-person contact should be adhered to in all participants, it may be necessary to 904 
discontinue ongoing in-person research activities for those at the highest risk for infection 905 
and poor outcomes. In-home neuromodulation or treatment options in the daily care units for 906 
older people may be a particularly good option for these individuals. Regardless of 907 
comorbidities, labs/clinics working with older adults should adhere to the highest standard of 908 
safety for minimizing COVID-19 transmission when continuing in-person research activities.  909 
 910 
Vulnerable sub-populations of older adults also include those with multiple chronic illness and 911 
low performance status, such as those receiving supportive services within the retirement 912 
communities (NORC) or community-based patients receiving specialist-level palliative care. At-913 
home tES paired with telehealth solutions has been shown feasible in these vulnerable sub-914 
populations. With proper COVID-19 precautions, screening and PPE protection, non-invasive 915 
neuromodulation may provide an option for symptom management in home settings.  916 
 917 
 918 
8 Examples of Best Practices in Brain Stimulation Labs/Clinics across the World  919 
8.1 Example 1, NYU Remotely Supervised or RS-tDCS: In the Department of Neurology at 920 
NYU Langone Health in midtown Manhattan, a protocol for remotely supervised tDCS (RS-921 
tDCS) [43-45] has been systematically developed and validated over the past five years with the 922 
goal of increasing access to treatments for larger sample sizes and to extend the number of 923 
treatment sessions. To date, using this protocol, >5,100 remotely supervised at-home sessions 924 
have been delivered to patients with MS [46, 47] and other neurological conditions such as PD 925 
[48] and cerebellar ataxia [49] and following ECT [50], targeting behavioral outcomes such as 926 
cognitive and motor functions and fatigue. While reducing patient time and costs was the 927 
original goal of the RS-tDCS protocol [51], the COVID-19 clinical research pause demonstrated 928 
the broad utility of remotely supervised at-home treatment for clinical trials. To date, there are 929 
two ongoing RCTs in MS participants, one pairing tDCS with cognitive training for 30 daily 930 
sessions over 6 weeks (National MS Society), and the other pairing tDCS with upper extremity 931 
motor exercises (US DoD) for 20 daily sessions.  932 
 933 
The research team prepared lab computers in advance of the research pause to administer the 934 
video visits off-site. Research participants were able to continue their daily treatment sessions 935 
without interruptions. We then obtained IRB approval to obtain informed consent for these trials 936 
remotely and have continued to enroll new participants. We have coordinated shipping of study 937 
equipment in “kits” to our participants that includes a preprogrammed tDCS device, headset, 938 
single-use sponge electrodes, a preconfigured laptop computer for the video visits and survey 939 
administration for outcomes. In the motor training trial, equipment for the daily exercises and 940 
assessment measures is also included. Study materials preparation and shipping (incoming and 941 
outgoing) follow a checklist protocol for enforcement in the policy for cleaning and disinfecting of 942 
study materials with all equipment marked for visual confirmation of sanitization. A third ongoing 943 
study (National Institutes of Health, NIH) that required baseline and treatment end neuroimaging 944 
visits was able to continue the treatments for the current participants but with enrollment on hold 945 
until research neuroimaging visits are resumed. 946 
 947 
Due to the high demand for access to tDCS from patients with MS (e.g. those who have had 948 
positive benefit in a clinical trial) as well as those with other chronic neurological conditions, we 949 
received institutional approval for a clinical tDCS service in December of 2019 as innovative 950 
care. This service was launched through the NYU Langone Virtual Health platform to provide 951 
video visits as telemedicine using our RS-tDCS procedures adapted for clinical use. Patients 952 
are loaned the tDCS device and headset, with a baseline clearance evaluation and then an 953 
intake visit with agreement forms and device orientation. The virtual visits operate directly 954 
through Epic [52] as is now system-wide throughout the NYU Langone Health system for 955 
implementation of telemedicine. Patients in the service currently include those with cognitive or 956 
motor symptoms of MS, mild cognitive impairment, and ataxia [49]. We also have provided the 957 
clinical treatment to patients with traumatic brain injury, post-stroke aphasia, and depression 958 
and cognitive impairment following ECT [50]. There has been no alteration of this clinical service 959 
during COVID-19 and we are able to see new patients through the outpatient telemedicine 960 
platform. 961 
 962 
8.2 Example 2, University of Minnesota, Pediatric Transcranial Direct Current Stimulation: 963 
Similar to adults, tDCS has been found to be well tolerated by children and has promising 964 
clinical effects [53]. The challenge of pediatric in-home telemedicine methods includes safety 965 
and parental compliance [54]. Considering that neuromodulation performed remotely or in the 966 
home setting in children incorporates a vulnerable population and also involves parents/legal 967 
guardians, assessments of safety, reliability and adherence are expanded beyond the construct 968 
of adult studies, and the investigator’s role in education and remote oversight pivotal. 969 
 970 
For over a decade, our Pediatric Neuromodulation Laboratory has pioneered protocols 971 
incorporating neurorehabilitation and neuromodulation. The potentially devastating impact on 972 
access to rehabilitation therapies due to the COVID-19 stay-at-home mandate on families and 973 
children with disabilities has yet to be fully realized. Telerehabilitation, as an alternative means 974 
to access rehabilitation intervention, has been successfully and feasibly performed in diverse 975 
populations of children with disabilities and by diverse telerehabilitation strategies [54]. 976 
Considering the construct, telerehabilitation in children has been reported to initially involve 977 
face-to-face discussion and education for both the parents and the child [55]. Additionally, 978 
specific considerations are indicated for pediatric populations, and integration of parents. In a 979 
pediatric telerehabilitation study aiming to increase treatment opportunities in cognitive training 980 
for children, Corti et al. integrated assessments of the feasibility of interventions and the study 981 
design in the home setting [55]. Key aspects of these assessments included ‘accessibility, 982 
training compliance, technical smoothness and training motivation’, along with assessments of 983 
recruitment, enrollment and retention. The authors found integration of the assessments to 984 
establish the study well-suited and remarkably high adherence to the protocol. Inherently, 985 
integrating tDCS with telerehabilitation would raise unique considerations, at the forefront-safety 986 
and reliability-with tDCS applications. To date there are no current publications surrounding 987 
pediatric tele-neuromodulation. Therefore, to adapt our current clinical research 988 
neuromodulation study to a tele-neuromodulation neuromodulation model with supervision for 989 
children who are diagnosed with stroke at or around the time of birth, we are currently 990 
integrating guidelines established by Charvet et al, [47, 56] and further work in adult stroke by 991 
Van de Winckel et al [57].  992 
 993 
Our past studies have integrated repetitive transcranial magnetic stimulation (rTMS) and tDCS 994 
with intensive rehabilitation in the pediatric population with perinatal stroke and resultant 995 
cerebral palsy. Now with our latest study, ‘Single -Session tDCS in Cerebral Palsy’, [58] we are 996 
investigating the neurophysiology and behavioral outcomes surrounding tDCS in children with 997 
varying forms of circuitry. We had safely and feasibly completed sessions in 19 children with 998 
stroke by the time COVID-19 put our study on hold. However, from the commencement of this 999 
study, this study garnered local, national and international interest from families of children with 1000 
stroke, many traveling great distances and incurring staggering related costs of travel to 1001 
participate. The COVID-19 challenge has now encouraged us to consider how to potentially 1002 
integrate tele-neuromodulation for children at home and could allow a broader catchment area 1003 
of families previously unable to travel and enroll. Integrating accessibility and compliance in 1004 
these unique teams of parents/children with cerebral palsy, our remote training and education 1005 
laboratory ‘tDCS supervisors’ will incorporate training the ‘lay assistant’ (parent) as to tDCS 1006 
delivery, and the ‘tDCS user’ (child). For ease of tDCS electrode placement, integration of a pre-1007 
marked skull cap with 10-20 electroencephalogram system electrode coordinates, indicating the 1008 
C3 C4 locations to approximate the primary motor cortex will facilitate anode/cathode 1009 
positioning based on the indicated montage. Assessments of reliability of set-up, and electrode 1010 
placement, and prior to commencing the stimulation sessions and monitoring tolerance and 1011 
impedance will be paramount, along with establishing a consistent and reliable method of 1012 
remote communication (e.g. Zoom) during the set-up, stimulation session, and pre/post 1013 
assessment trials. 1014 
Integrating a COVID-19 response to continue neuromodulation in the pediatric population with 1015 
perinatal stroke and resultant cerebral palsy, as well as lack of access recruitment feedback 1016 
garnered from our previous work with families nationally and internationally, this remote 1017 
investigation will inform future larger externally-funded studies to remotely integrate children 1018 
with mobility, financial, and access challenges (e.g. rural communities). 1019 
 1020 
8.3 Example 3 NIBS at the University of Magdeburg, Germany: Most of the tDCS-tACS 1021 
clinical trials were stopped in middle of March, 2020, there is one trial running with NeuroConn 1022 
Mobile devices. The aim of this phase II study is to collect information about the efficacy of 10 1023 
Hz tACS in the treatment of glaucoma [59], using a domiciliary tACS. The number of possible 1024 
stimulation sessions is fixed (34 during 14 weeks) which cannot be changed remotely –and at 1025 
this stage will not be changed due to safety reasons. To the best of our knowledge, this is the 1026 
longest stimulation duration that was ever applied in this patient group. Furthermore, none of the 1027 
stimulation parameters can be changed during treatment, only by shipping a new stimulation 1028 
module to the patients. Patients are required to document adverse events and side effects in a 1029 
diary and the stimulation module is saving the parameters of each session, which t can be 1030 
downloaded in the study center. Unfortunately, several patients were not able to visit the center 1031 
at the end of the stimulation session, therefore the objective measurements (e.g. perimetry) are 1032 
still missing. The state of the patients are followed by regular phone calls, two of them indicated 1033 
to terminate the participation in the trial, due to high levels of personal stress. 1034 
 1035 
8.4 Example 4, Example from a Multisite Definitive Phase III tDCS Trial at University of 1036 
Florida and University of Arizona - Augmenting Cognitive Training in Older Adults: the 1037 
ACT Trial: The ACT trial is a multisite definitive Phase III clinical trial that investigates the 1038 
benefits of pairing tDCS with cognitive training in older adults to remediate age-related cognitive 1039 
decline and potentially prevent onset of mild cognitive impairment and dementia [60]. ACT 1040 
involves a 3-month cognitive training intervention paired with 20 in lab/clinic sessions of either 1041 
active or sham tDCS. Participants undergo cognitive training and tDCS 5 days/week for the first 1042 
two weeks, then complete cognitive training at home on a study supplied laptop 4 days per 1043 
week with 1 day per week in lab/clinic for stimulation. At present, the ACT trial has randomized 1044 
307 of 360 older adults targeted for randomization in the trial. As this trial works with a 1045 
population at high risk for poor COVID-19 outcomes, in-person study activities were stopped on 1046 
March 13, 2020. At this time, 22 participants were actively in the intervention phase of the trial. 1047 
As ACT is a definitive Phase III trial near its completion, a late phase change to at-home tDCS 1048 
procedures would significantly undermine trial integrity for evaluation of definitive benefits from 1049 
tDCS paired with cognitive training, as only a small subset of participants would receive the 1050 
alternative intervention approach. Even were the current COVID-19 outbreak to occur earlier in 1051 
the trial, a significant change in intervention procedures would likely not be feasible for a Phase 1052 
III trial. In addition, the primary outcome measure in the ACT trial is currently not available 1053 
through telemedicine, further preventing continuation of trial activities through a fully remote 1054 
process. In ACT, 22 participants whose interventions were interrupted will need to be replaced. 1055 
In addition, approximately 40 participants will miss the timing of their final 1 year follow-up 1056 
assessment and MRI visits as of the current date. Careful consideration with the trials data 1057 
safety monitoring board and funding agency program office will need to be given regarding 1058 
whether these 40 participants will need to be replaced in the trial as well. Pre-COVID-19, ACT 1059 
was within 14 months of completion. With the loss of 22 participants, the study will likely not be 1060 
completed for 24-26 months. Should the 40 participants missing their 1 year time point need to 1061 
be replaced, trial completion could be delayed to 36 months or more. While the extent of delay 1062 
is still to be determined, this serves as a poignant example of how COVID-19 is directly 1063 
impacting the speed of progress in medical science. This example also further highlights the 1064 
critical importance of advancing remotely supervised methods of neuromodulation 1065 
administration. In ACT, participants complete cognitive training at home for a large portion of the 1066 
trial. Were this initially paired with remote tDCS, the overall impact on ACT would be 1067 
significantly reduced. However, lack of availability of primary outcome measures for remote 1068 
online or tele-administration would have still led the ACT trial to pause activities. Thus, it is also 1069 
important to note that there is a strong need for overarching work attempting to facilitate remote 1070 
assessment activities for clinical trials.  1071 
 1072 
9. NIBS New Opportunities 1073 
This section focuses on not simply accommodating the pandemic situation but using this period 1074 
to update or enhance existing NIBS practices using techniques that have already been 1075 
validated. We specifically consider telemedicine approaches using tDCS (9.1), accelerating in-1076 
clinic TMS procedures (9.2), and introducing new NIBS protocols to address existing and 1077 
emerging COVID-19 morbidities (9.3).  1078 
 1079 
9.1 Tele-neuromodulation (in home)  1080 
Considering past remote neuromodulation studies and current COVID-19 related challenges, 1081 
‘Tele-neuromodulation’ holds one of the greatest opportunities for innovation and growth in the 1082 
NIBS field right now [61]. Moreover, it is generally the case that administration of remote 1083 
neuromodulation would allow those with limited accessibility (e.g. mobility issues, geographic 1084 
location, financial barriers, limited access to communication technologies) to interventions not 1085 
previously realized. Rapidly expanding investigations of tDCS in the home setting in adult 1086 
populations have been well-tolerated and shown high compliance, and low drop-out rates in 1087 
diagnoses such as depression [62], stroke [57], MS [44, 46, 47] PD [48], and amyotrophic lateral 1088 
sclerosis [63], as well as in seriously ill multi-symptomatic palliative-care patients . Considering 1089 
the acute challenges in neuromodulation access for all, an additional consideration is the 1090 
expanding field of pediatric telemedicine, with implications for safe and feasible 1091 
neuromodulation applications in the home setting [54, 64, 65]. 1092 
 1093 
As outlined in case examples (Sections 8.1, 8.2), for those centers already engaged in remote 1094 
supervised tDCS, strategic and incremental protocols changes allow continuation (and even 1095 
expansion) of protocols. For those centers exploring transition of in-center tDCS to remotely 1096 
supervised tDCS, there are well established principles under the Remote Supervised rubric that 1097 
allow home-based tDCS with compromising reproducibility [46] and detailed supporting 1098 
documentation [45, 56, 65, 66]. 1099 
 1100 
For those protocols providing NIBS treatments that inherently require in-center application, 1101 
notably TMS and ECT, and where COVID-19 related streamlining of in-center protocols is not 1102 
practical (for specific patients), transition to home-based tDCS may be considered as a valid 1103 
alternative option. There is evidence that tDCS can extend the benefit of TMS or ECT 1104 
treatments [50, 67]. When ECT and TMS services are not available the operant decision is not 1105 
the comparative efficacy of various NIBS techniques [68] but the risk/benefit ratio of trialing 1106 
tDCS. The risk of tDCS is considered non-significant and safe, including across clinical 1107 
populations [69-71] - indeed tDCS is broadly applied to healthy subjects (e.g. college students; 1108 
[72]). Specifically for major depressive disorder, controlled trials [73-75], meta-analysis [68, 76, 1109 
77] and expert consensus [78] suggest tDCS is comparably effective with significantly less 1110 
adverse events than drug therapy. Consideration for deploying remote-tDCS treatment should 1111 
be based on the latest clinical trial data [56]. 1112 
 1113 
9.2 In-clinic Brain Stimulation  1114 
While the portability and cost of tES devices lend themselves to a relatively easy shift toward in-1115 
home usage and training, most TMS studies are currently tied to a fixed clinical or laboratory 1116 
location, which is often in a hospital environment. This is a challenge for researchers that are 1117 
weighing the cost benefit ratio of restarting their therapeutic intervention trials in an environment 1118 
wherein participants and staff members may be exposed to the COVID-19 virus. The balance is 1119 
likely different for mechanistic TMS studies designed to characterize a disease or biology itself, 1120 
without any anticipated therapeutic effect.  1121 
 1122 
That said, there are several sites conducting therapeutic TMS clinical trials across the globe that 1123 
have been allowed to remain open through the COVID-19 epidemic. Even more are resuming 1124 
operations as universities, hospital systems, and countries at large begin to reopen clinical 1125 
research operations (Section 2). In fact, while the majority of TMS research trials were put on 1126 
pause during the COVID-19 period, clinical delivery of TMS continued in many U.S. states and a 1127 
variety of countries for individuals with treatment’ refractory major depression, often with 1128 
modified clinical workflows to ensure safety related to COVID-19. Below we will outline topics 1129 
that are common to many clinical services and trials that remained open (or are reopening) as 1130 
well as some new areas for innovation and risk-reduction when performing TMS in the COVID-1131 
19 era. 1132 
 1133 
9.2.1. Converting Consent, Screening, and Follow-Up Visits to Electronic, Voice, or Video 1134 
Format. A common theme echoed in this manuscript is to shift any non-essential in-person visit 1135 
to electronic/video format. For many research studies there is a Consent Visit, Screening Visit, 1136 
and Follow-Up visits. One of the benefits of the COVID-19 crisis has been a widespread 1137 
familiarity and increasing comfort with video conferencing software (e.g. Zoom, Webex, VSee). 1138 
It is important to ensure the security of the videoconferencing platform when connecting with 1139 
patients or study participants, however, with respect to institutional requirements for HIPAA 1140 
compliant communications. Given that TMS studies often require at least one in-person 1141 
intervention visit, transforming our protocols to embrace video techniques for all other visits 1142 
would improve the risk benefit ratio for the staff and the participants. Additionally, research 1143 
groups may want to consider adding “COVID-19-related illness” as an exclusionary criteria or as 1144 
part of the risks for participating in a research study which relies on multiple in-person visits 1145 
(should the institution deem this necessary).  1146 
 1147 
9.2.2. Utility of Theta Burst Stimulation. Fixed frequency rTMS (e.g. 10 Hz) is the oldest and 1148 
most established stimulation protocol and has been FDA-approved for use in treatment resistant 1149 
major depressive disorder for many years. In recent years however, bursting frequency 1150 
protocols (e.g. theta burst stimulation (TBS)) have emerged as highly potent and temporally 1151 
efficient forms of brain stimulation; that is, 600 pulses of intermittent TBS (iTBS) delivered over 1152 
45 seconds result in an elevation in cortical excitability comparable to 2000 pulses of 10 Hz 1153 
TMS delivered over 15 minutes [79]. The effects of a single session last approximately 30 1154 
minutes, but repeated sessions have similar durability and efficacy as 10Hz rTMS [80] 34 and 1155 
were first described in the motor cortex. Several recent, clinical trials applying TBS to the 1156 
dorsolateral prefrontal cortex have demonstrated treatment outcomes with iTBS are comparable 1157 
to treatment outcomes with traditional 10 Hz rTMS in major depressive disorder. Furthermore, 1158 
these protocols have similar side-effects, safety, and tolerability profiles. The advantages of 1159 
elevated potency and efficiency are coupled with a rigorous biologic foundation as theta is an 1160 
endogenous neural rhythm associated with learning and memory. By using TBS, the number of 1161 
patients treated per day with current rTMS devices can be increased several times without 1162 
compromising clinical effectiveness or safety. In this COVID-19 era, one way to minimize the 1163 
length of the time that a participant or patient has to be present in the room with a staff member 1164 
would certainly be for investigators to consider using bursting frequency rTMS protocols which 1165 
appear to be more efficient pulse-to-pulse. The shorter duration of the stimulation session also 1166 
provides more flexibility when considering changes in workflow and schedules to ensure that 1167 
patients do not overlap and thorough infection control measures are applied after every session.  1168 
 1169 
That said, there has been some concern that the response to theta burst stimulation is highly 1170 
variable [80, 81]. Although there have been very few sham-controlled comparisons of fixed 1171 
frequency versus theta burst frequency TMS, the largest study to directly compare these 1172 
protocols (which was not sham controlled), did not find a difference in the variability or the 1173 
durability of response to 20 sessions of iTBS compared to conventional 10 Hz TMS in patients 1174 
with depression [80]. While the relative efficacy and durability of these protocols is an empirical 1175 
question that remains unanswered, in the COVID-19 era it seems that greater investigation into 1176 
the factors that increase theta burst efficacy are warranted.  1177 
  1178 
9.2.3. Accelerated TMS Delivery. The development of novel, accelerated TMS dosing 1179 
strategies is another opportunity for clinical researchers. Previous studies have demonstrated 1180 
that delivering multiple TMS sessions per day has similar efficacy to a single TMS session per 1181 
day when the total number of TMS administrations is equal [82-84]. Given that the total number 1182 
of TMS sessions appears to be a critical factor in behavioral change, these concentrated dosing 1183 
protocols would be attractive to both patients and providers. While these protocols are being 1184 
explored in research laboratories however, there is still a gap in our knowledge regarding the 1185 
parameters that optimally balance efficiency with long-term efficacy. In one of the most 1186 
concentrated TMS protocols to date Williams and colleagues (2018) recently published a study 1187 
of 6 individuals with highly refractory depression (5 days, 10 sessions/day, 1800 pulses of 1188 
iTBS/session, 50 minute inter-session interval) which demonstrated that this rapid dosing 1189 
schedule was feasible and was effective as a rapid antidepressant [85, 86]. Galletly and 1190 
colleagues (2010), for example, elegantly demonstrated that TMS delivered 3 times/week 1191 
achieved overall similar outcomes to 5 times/week as long as the overall number of 1192 
administrations was the same (18-20 administrations) [87]. While most accelerated TMS studies 1193 
are being done in Major Depressive Disorder, they are also being used in many currently 1194 
recruiting drug and alcohol treatment research trials [88-93]. These protocols reflect dosing 1195 
schedules that are likely more tenable for patients who likely have job and family responsibilities 1196 
(often 3 days per week versus the standard 5 days per week). They are being used by 1197 
researchers around the world. By decreasing the number of times a participant or patient needs 1198 
to come to the laboratory/clinic, accelerated TMS schedules will also minimize the number of 1199 
days that individual spends out of the house, the number of times they use public transportation, 1200 
and the number of other person-encounters they have over the course of their treatment (as 30 1201 
sessions of TMS could be given in as little as 3 or 6 days as has been tried at various 1202 
institutions in the United States). On the other hand, although it reduces the total time of TMS 1203 
treatment, patients need to stay longer in the TMS environment, from one or two hours 1204 
mounting up to the entire day. 1205 
  1206 
9.2.4. Other Technologies, such as Portable TMS. A few other techniques and opportunities 1207 
for innovative TMS protocol adaptations include greater reliance on neuronavigation for reliable 1208 
and fast TMS coil positioning (as described in previous sections of this manuscript) and the 1209 
delivery of TMS in off-site community clinics wherein the participant may have less exposure to 1210 
potential COVID-19 carriers in the hospital environment. Perhaps the most provocative (but still 1211 
chimerical) opportunity is for increased investment and innovation in a portable means for TMS 1212 
delivery. There are several patents currently for portable TMS devices (e.g. for the treatment of 1213 
migraine attacks Starling et al. [94]) and several papers have recently been published 1214 
describing personalized TMS helmet designs which stabilize the coil [95] and wearable TMS coil 1215 
designs [96]. Currently, however, there are no devices being made for commercial use. The 1216 
ability to distill the power of electromagnetic induction as a brain stimulation tool into a 1217 
briefcase-sized device has the potential to revolutionize non-invasive neuromodulation as a 1218 
field. To see this materialize from a fantasy to a reality on the tails of the COVID-19 crisis could, 1219 
in fact, be one of the biggest achievements the neuromodulation field may gain from this 1220 
experience. It will, however, take talent, time, and investment to make this happen. One should 1221 
also balance the safety balance of reducing exposure to the coronavirus with the exposure to 1222 
the yet unclear risks of patient self-application of home-based TMS. 1223 
 1224 
9.2.5. Consideration of tDCS as Alternative or Adjunctive Treatment. As discussed above 1225 
(Section 9.1). tDCS can be deployed at home with no or minimal required in-person interactions. 1226 
On a situation based, providing tDCS as an alternative to TMS or optimized the benefits of TMS 1227 
(e.g. tDCS for maintenance of TMS therapy) can be considered [97, 98]. 1228 
  1229 
In conclusion many of the TMS treatment trials that were temporarily halted in March 2020 1230 
around the world have begun to put strategies in place to return to enrollment and execution. 1231 
These decisions should be made with sensitivity to many factors including the potential risk of 1232 
COVID-19 exposure to the participants and staff for in-person visits and the potential benefit to 1233 
participants & patients of the intervention. Those trials involved structural or functional imaging 1234 
remains restricted based on the opening of imaging facilities. Similarly, any TMS trials involving 1235 
parallel in-person protocols (e.g. rehabilitation) are considered in totality. While there will be 1236 
many factors that influence this decision for each TMS study, there are some common themes 1237 
that will minimize risk (electronic visits when possible, accelerated treatment courses, shorter 1238 
pulse sequences like theta burst, use of technological methods such as neuronavigation and 1239 
scalp modeling to improve rigor and decrease contact) that not only improve the risk benefit 1240 
ratio but will likely lead to a reimagination of the future of TMS delivery- perhaps even launching 1241 
a new industry that merges the portability and affordability of tDCS devices with the benefits of 1242 
electromagnetic induction as a mechanism of inciting brain change. 1243 
 1244 
9.3 New Clinical Opportunities (Indications) with NIBS in the era of COVID-19 1245 
In response to the COVID-19 outbreak, initial psychological and emotional reactions such as 1246 
elevated levels of anxiety, fear, stress or anger and behavioral responses like social/physical- 1247 
distancing, stockpiling goods, PPE and disinfectants have been predicted based on previous 1248 
experiences [99], and then reported during the COVID-19 outbreak [100-103]. However, 1249 
precipitated psychological responses might progress into severe mental concerns which can 1250 
easily outlast the pandemic. Sleep disturbances, somatization, stress-related illnesses, post‑1251 
traumatic stress disorder (PTSD), anxiety disorders, depressive disorders and health risk 1252 
behaviors such as social isolation, substance abuse or suicide attempts might also surge [2, 1253 
102, 104]. Accordingly, depressive and post-traumatic symptoms have been constantly reported 1254 
and found to persist even 2.5 years after epidemics [105]. Evidence that similar symptoms are 1255 
present among health care professionals and the general population during the COVID-19 1256 
outbreak is already emerging from China, the epicenter of the outbreak [103, 106-108], and 1257 
from Europe as well [109]. 1258 
 1259 
The consequences of COVID-19 might be more immense in terms of the number of affected 1260 
and maybe in terms of symptom severity than previous outbreaks, not to mention its economic 1261 
and political impact and their effects on an individual level. Apart from new cases with mental 1262 
health issues, those already facing mental health problems or belong to a vulnerable population 1263 
might experience their symptoms worsening [110, 111]. Increased risk of COVID-19 infection or 1264 
potentially deteriorating mental health during the outbreak has been articulated concerning 1265 
patients with cancer [112], dementia [113], PD [114], chronic pain [115], MS [116] and drug 1266 
users [2]. 1267 
 1268 
In light of the potential surge of demand for mental health care, effective therapeutic options are 1269 
critical. NIBS is a promising and versatile tool to consider. The administration of magnetic fields 1270 
(i.e. TMS) or weak electrical currents (i.e. tES) induces long-term neuronal effects through 1271 
modulating neuroplasticity [117]. One of the first and most successful areas of NIBS application 1272 
is the use of HF-TMS over the left dorsolateral prefrontal cortex to alleviate depressive 1273 
symptoms that now has a level A evidence (i.e. definite efficacy) [4]. Interestingly, promising 1274 
results are emerging regarding the beneficial effects of NIBS on several clinical populations 1275 
suggesting transdiagnostic opportunities. Level B (probable efficacy) recommendation has been 1276 
proposed for the use of TMS in fibromyalgia, PD, MS, PTSD and stroke [5]. Evidence is less 1277 
conclusive on tES; however, level B evidence supports the utility of tDCS in depression, chronic 1278 
pain and fibromyalgia [6]. Moreover, prosperous results suggest the potential efficacy of NIBS in 1279 
several other disorders e.g. in anxiety disorders [118], dementia [119], obsessive-compulsive 1280 
disorder [120, 121] and pediatric attention-deficit hyperactivity disorder [122].  1281 
In an outbreak situation, adaptation skills and flexibility are essential to adjust behavior to the 1282 
new regulations; thus, to mitigate the spread of the virus. Cognitive control is impaired in several 1283 
conditions [114, 123]; however, NIBS has successfully ameliorated cognitive impairment in 1284 
different patient groups [123-125]. Another important skill, emotion regulation has improved in 1285 
patients with anxiety disorders with the effects being sustained for 3 months after TMS [126]. 1286 
Depressive symptoms, anxiety and PTSD emerging or being accelerated by the COVID-19 1287 
pandemic [102] might also be successfully mitigated with NIBS based on previous research [4, 1288 
127, 128]. Furthermore, stress is also known to exacerbate disease-related symptoms such as 1289 
the motor symptoms of patients with tic disorders or PD [114, 129, 130]. Preliminary evidence 1290 
indicates the beneficial effects of TMS on motor performance as well [131, 132]. 1291 
 1292 
Recently, the possibility of COVID-19-associated nervous system diseases has also been 1293 
clinically proven by detecting the ribonucleic acid (RNA) of the virus in the cerebrospinal fluid of 1294 
a patient [133]. Neurological symptoms such as impaired consciousness, headache, dizziness 1295 
and taste or smell impairment are not uncommon [134]. Therefore, the long-term follow-up and 1296 
monitoring of severe cases of COVID-19 in terms of neurological symptoms is highly advised 1297 
[135]. Through the enhancement of neural plasticity, some COVID-19-related neurological 1298 
residual symptoms might be attenuated by NIBS. In a rat model, TMS has been found to reduce 1299 
inflammation after focal brain injury [136] and to decrease the production of proinflammatory 1300 
cytokines in patients with PD [137]. Moreover, patients with disorders of consciousness have 1301 
shown neurobehavioral and electrophysiological gains after multiple sessions of NIBS [138-1302 
140]. Therefore, anti-inflammatory potential and neurological utilization of NIBS might also be 1303 
investigated. 1304 
 1305 
Finally, there may be opportunities to apply NIBS in the broader context of changing medical 1306 
protocols. This could span changing methods and access to prescribed medications (e.g. ability 1307 
to diagnose, monitor for adverse events) as well as any consideration of unexpected 1308 
interactions between drugs (e.g. psychotropics) and antiviral medication. A general feature of 1309 
NIBS is its non-drug non-systematic application nature, non-addictive nature, and ability to 1310 
terminate or adjust dose (in clinic or remote for home-based treatment) and vice versa. Clearly, 1311 
there is potential for NIBS as a unique treatment tool in the fight against the medical and 1312 
psychological after-effects of the COVID-19 outbreak.  1313 
 1314 
10. Conclusion 1315 
The COVID-19 pandemic, just like all crises, has yielded challenges for researchers, clinicians, 1316 
participants and patients, but also lessons to learn from and new opportunities to pursue. By 1317 
synthesizing the experiences of experts from all over the world, this consensus paper 1318 
establishes practical recommendations to follow in operationalizing NIBS during COVID-19 1319 
pandemic, mitigating the risk of infections, and in preparing the NIBS community for any future 1320 
epidemic/pandemic. Indeed, as we emerge from the current pandemic, the number of people 1321 
who require innovative treatments such as NIBS due to direct and indirect effects of COVID-19 1322 
onto the brain and mental health will significantly increase. This burden on the health care 1323 
systems mandates broader investigation and adoption of therapeutic solutions such as the use 1324 
of NIBS. For NIBS laboratories and clinics to contribute to the ease the burden of the pandemic, 1325 
it is necessary to re-establish operation with prudent protocol modifications as soon as possible. 1326 
  1327 
Maintaining ongoing and restarting operations at NIBS clinics and research institutions across 1328 
the world requires accommodation to strict measures (namely social/physical distancing) 1329 
introduced due to the COVID-19 outbreak The suddenness and severity of initial restrictions 1330 
resulted in significant disruptions to ongoing clinical treatment and trials (spanning suspension 1331 
recruitment of participants, interruption of ongoing treatment, to complete suspension of in-1332 
person activities). The degree of interruption varied; for example, in-person non-clinical (non-1333 
essential) work was largely halted while remote-tDCS clinical activity continued. Interruption of 1334 
ongoing trials is compounded by overall operational and programmatic uncertainties e.g. the 1335 
situation of students and early career scientists, financial concerns. The overarching concern is 1336 
when and how specific clinical and laboratory work can be resumed and what precautions are to 1337 
be adopted. This document provides guidelines for maintaining and resuming NIBS operations.  1338 
 1339 
We distinguish three phases of procedural responses (immediate COVID-19 impact, current 1340 
practices, and future preparation), with current reactions of the NIBS community to the COVID-1341 
19 pandemic largely in early phases with reactions aiming to limit disruption to ongoing 1342 
protocols. However, streamlining and expanding NIBS services is now ongoing. 1343 
 1344 
Based on the analysis of international experts with domain relevant expertise covering NIBS 1345 
technology, clinical services, and human trials, we formed recommendations to ensure the 1346 
safety of participants, researchers and staff members during the re-establishment of access to 1347 
NIBS clinical services and research operations. Apart from the obvious preparations (e.g. 1348 
sanitization and social distancing protocols and remote data acquisition where possible), 1349 
recommendations are also made regarding protocol optimization, methodological good 1350 
practices, the support of all stakeholders including early career scientists. To foster this process, 1351 
a checklist is also provided in the article. Mitigation plans to reduce the risk of infection for 1352 
subjects/participants and research/clinical staff are preeminent but should be based on the 1353 
applicable national and institutional guidance and scientific understanding to avoid being 1354 
misdirected or unduly burdensome. Recommendation on precautions are also discussed 1355 
considering pediatric research, older adults, patients with addiction, stroke, MS or other chronic 1356 
neurodegenerative/inflammatory disorders.  1357 
 1358 
As explicated through this document, appropriate safety protocols are crucial to provide NIBS 1359 
for those who require mental health care regardless of, and also aggravated by, the outbreak. 1360 
With well-coordinated and strategic responses, the NIBS community can play an expanding role 1361 
in managing the burden related to the COVID-19 pandemic while continuing to generate clinical 1362 
and scientific regarding the efficacy and underlying mechanisms of NIBS. As we have discussed 1363 
above, expanding clinical trials with telemedicine-based NIBS are of high impact in the current 1364 
situation and considering future outbreaks and longstanding need for vigilance. Since tES 1365 
devices are more easily transportable and simple to use, the remote application of tES is more 1366 
supported in contrast to TMS. Guidelines [46, 56] and empirical experience [140-142] regarding 1367 
the at-home applications of tDCS are available. Experiences gained through this process as 1368 
well as new perspectives gathered during the challenging era of COVID-19 might delineate new 1369 
research and therapeutic goals and become invaluable when preparing for future outbreaks 1370 
 1371 
The interest in telemedicine-based solutions has especially increased among the NIBS 1372 
community [61] and the experiences gained from such studies conducted during the outbreak 1373 
will be broadly valuable. Generally, remote NIBS solutions extend the availability of 1374 
neuromodulation, and can reduce costs of increasing the trial sample sizes and treatment 1375 
duration. The adaptation process of some in-clinic TMS solutions that sustained operation 1376 
during the pandemic and protocols to reduce contact is addressed. 1377 
 1378 
The NIBS community has faced varied degrees of disruption that has broadly challenged 1379 
laboratories and clinics across the globe. By working around evolving restrictions and 1380 
uncertainties, strategic (and not unduly burdensome) implementation of applicable safety 1381 
procedures, and adaptation of protocol components to limit in-person activities, access to NIBS 1382 
must be continued and re-established rapidly. In this article, approaches and practical 1383 
recommendations have been provided. Indeed, if further outbreaks arise, the NIBS community 1384 
will be better prepared for them.  1385 
 1386 
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Table 1. COVID-19 and International Accommodations in Brain Stimulation Clinic Setting. 
Survey data were collected from April 30, 2020 to May 6, 2020. To date, data on 9 institutes have been collected from 7 countries. Phase 0 
refers to the challenges that affected clinical activities with respect to COVID-19. Phase 1 refers to the activities that have been implemented in 
response to the pandemic. Phase 2 refers to the precautions planned or already implemented during the reopening of NIBS clinics. 
Country Name of the institution 
Start date of 
restrictions 
(Planned) date of 
easing the 
restrictions 
Restrictions Phase 0 Phase 1 Phase 2 
Australia Monash University 
and Epworth 
Healthcare 
Beginning of April To be decided,  
 
returning to campus 
is allowed after 
June 1, 2020 
• Inpatient and outpatient 
treatment services are 
still allowed 
• Assessments are done 
via telehealth 
• None mentioned • Implementation of 
teleconsultation 
• Screening system 
developed  
• Screening remotely 
and in person 
• Measuring body 
temperatures 




Ghent University March 17, 2020 
 
May 4 or May 11, 
2020 
 
• COVID-19 sub-wards 
• Non-urgent treatments 
and ambulatory 
consultation suspended 
• rTMS maintenance is 
allowed 
• ECT is allowed based 
on severity 














• To be decided 
India Kasturba Medical 
College, Manipal 
Academy of Higher 
Education 
March 23, 2020 
 
Not specified • Interruption of non-
emergency services 
• Rotating schedules to 
provide essential 
services 
• Patients and staff 
under lockdown 
• Implementation of 
tele-consultation 
for the follow-up 
of old patients 
• Basic hygiene 
precautions* 
Italy Gallimberti & 
Partners (private 
addiction clinic) 
March 9, 2020 
 
May 18, 2020 
 
• Interruption of clinical 
protocols  
• Only COVID-19 free 
patients are admitted 
• Data loss from 
ongoing studies 
• Increase of 
psychological 
distress in addicted 
patients 





• PPE or transparent 
face shields  
• Rescheduling patients 
(only one at a time) 
• Measuring the 
temperature of 
patients 
Italy IRCCS Santa Lucia 
Foundation 
March 9, 2020 
 
May 18, 2020 
 
• Interruption of clinical 
protocols 
• Home-based 
protocols are not 
approved yet 
 • PPE or transparent 
face shields 
• Rescheduling patients 
(only one at a time) 
• Measuring the 
temperature of 
patients 
Russia National Medical 
Research Center 
for Psychiatry and 
Neurology, St.-
Petersburg 
March 26, 2020 Approximately mid-
May 2020 
 
• Interruption of all clinical 
activities 
• None mentioned • Teleconsultations 
for some patients 








March 6, 2020 To be decided, 
maybe January 
2021 
• Interruption of care 
services for community-
based aphasic stroke 
patients 
• Interruption of remote 
outpatient and 
treatment services 
• Redeployment of 







• Home-based tDCS 
• Shift schedules for 
staff members 
• Social distancing 
measures 






March 20, 2020 May 18, 2020 • Interruption of all 
inpatient and outpatient 
visits 
• No visitors allowed in 
the hospital 
• Interruption of 
research activities 
• Implementation of 
teleconsultation 
• Questionnaire or 
checklist to assess 
COVID-19 risk 
• Testing for COVID-19 
• PPE 
• Remote or home 
stimulation 
 
NY, USA NYU Langone 
Health, New York 
NY 
March 10, 2020 Approximately mid-
May 2020 
• Interruption of all 
outpatient visits  
 
• Redeployed 
therapy staff to 
work remotely 








• Approved for new 
patient enrollment 


















• Continue treatments 
and enroll new 
patients remotely 
• Follow institutional 
guidelines for infection 
control for any onsite 
new patient 
evaluations 
• Shift schedules for 
staff members 
• Social distancing 
measures for clinical 




rTMS: repetitive transcranial magnetic stimulation; ECT: electroconvulsive therapy; tDCS: transcranial direct current stimulation; VNS: vagus nerve 
stimulation; DBS: deep brain stimulation; PPE: personal protective equipment. 
basic hygiene precautions*: PPE, sanitization, social distancing 
Table 2. COVID-19 and International Accommodations in Brain Stimulation Research Setting 
Survey data were collected from April 30, 2020 to May 6, 2020. To date, data on 28 institutes have been collected from 17 countries. Phase 0 
refers to the challenges that affected research activities with respect to COVID-19. Phase 1 refers to what activities have been implemented in 
response to the pandemic. Phase 2 refers to the precautions planned or already implemented during the reopening of NIBS labs. 
Country Name of the institution 
Start date of 
restrictions 
(Planned) date 
of easing the 
restrictions 













June 1, 2020 
• Interruption of ongoing 
preclinical studies 
• TMS studies 
suspended 
• Data loss from ongoing 
studies 
• Interruption of data 
collection 
• Re-organization of 
tDCS studies for remote 
administration 
• Follow-up of recruited 
participants 
• Implementation of 
teleworking 
• Data collection from 
remote studies 
• Basic hygiene 
precautions* 
Austria University of Graz March 11, 
2020 
Mid-May • All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Staff working in 
rotations 
• Implementation of 
teleworking 
• Implementation of 
teleconferencing 






• Sanitization protocols 









To be decided • All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Implementation of 
teleworking 
• Implementation of 
teleconferencing 
• To be decided 
Belgium 
 
Ghent University March 17, 
2020 
 









• Interruption of data 
collection  
• Data loss from ongoing 
TMS studies 
• Implementation of 
teleworking 
• Implementation of 
teleconferencing 
• Continuation of 
teleconferencing 
• Basic hygiene 
precautions* 
Brazil Federal University 




To be decided • All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Implementation of 
teleconferencing 
• Basic hygiene 
precautions* 
• Checklists for staff and 
patients 
• Rescheduled treatment 
sessions 
• Shift schedules for all 
professionals 
• Individualized devices 
and single-use 
packages for stimulation 
Immunity passports 




end of July • All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Data mining 
• Computational 
modelling 
• Remote patient 
follow-up 
• Implementation of 
teleconferencing 




• Basic hygiene 
precautions* 
• Checklists for staff and 
patients 
• Rescheduled treatment 
sessions 
• Shift schedules for all 
professionals 
• Individualized devices 
and single-use 
packages for stimulation 









Likely May or 
June 2020 
 
• Interruption of most 
clinical operations; 
continuation of urgent 
patients and acute 
care 
• Interruption of data 
collection 
• Early career scientists 
losing time and 
opportunities 
• Virtual clinics 
• Pooling data across 
labs for new analysis 
opportunities  
 
• Priority to young early 
career scientists 
• Structured screening 
system 
China Shanghai Mental 
Health Center 
Jan 29, 2020 May, 2020 • All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Implementation of 
teleworking 












May, 2020 • All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Regular meetings for 
Journal Clubs were 
stopped  
• Implementation of 
teleworking 
• Implementation of 
teleconferencing 
• Basic hygiene 
precautions* 








To be decided, 
treatment-
related research 
is resumed after 
May 4, 2020 
• All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Delays in projects 
• Potential depletion of 
project funding 
• Implementation of 
teleworking 
• Implementation of 
teleconferencing 
• Daily updates on 
COVID-19 
• Training for all 
researchers 
• Mitigation plan based 
on national and 
international standards 
• Reopening gradually 
• Screening patients 
• Rescheduling patients 













after May 4, 
2020 
• All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Delays in projects 
• Potential depletion of 
project funding 
• Implementation of 
teleworking 
• Implementation of 
teleconferencing 
• Continuation of 
teleconferencing and 
remote work if possible 
• Sanitization protocols 
















• All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Having to close a study 
without meeting the 
predefined sample size 
• Implementation of 
teleworking 
• Implementation of 
teleconferencing 
• PPE  









May 15, 2020 
 
• All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Pause of recently 
started studies 
• Lower statistical power 
for studies terminated 
earlier 
• Implementation of 
teleworking 
• Implementation of 
teleconferencing 
• Shift schedule for all 
professionals 
• Rescheduled treatment 
sessions 
• Social distancing rules 







Not specified • Non-urgency activity 
suspended 
• Interruption of data 
collection 
• Implementation of 
teleworking 
• Implementation of 
teleconferencing 
• Basic hygiene 
precautions* 






April 4, 2020 • Interruption of all 
preclinical 
experiments 
• Interruption of all in-
person study activities 
 
• Interruption of data 
collection 
• Decreased number of 
sessions and incoming 
projects 
• Implementation of 
teleworking 
• Webinars 
• Basic hygiene 
precautions* 
• Measuring the 
temperature of patients 
• Assessment by a doctor 
at the reception 
• Instructions for patients 
and staff 
Italy Novella Fronda 
Foundation 
March 9, 2020 
 
May 18, 2020 
 
• All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Data loss from ongoing 
studies 
• Implementation of 
teleworking 
• PPE or transparent face 
shields 
• Rescheduling patients 
(only one at a time) 
• Measuring the 
temperature of patients 
Italy IRCCS Santa 
Lucia Foundation 
March 9, 2020 
 
May 18, 2020 
 
• Interruption of ongoing 
research 
• Interruption of data 
collection 
• Home-based protocols 
are not yet approved  
• Implementation of 
teleworking 
• PPE or transparent face 
shields 
• Rescheduling patients 
(only one at a time) 
• Measuring the 
temperature of patients 
Japan Nagoya Institute 
of Technology 
April 10, 2020 
Students are 
not allowed to 
access the 
University from 
March 9, 2020 
 
Likely May 7, 
2020 
• All ongoing studies 
and lab activities 
suspended 
• Financial burdens and 
uncertainties 
• Need to complete all 
preclinical research by 




• Implementation of 
teleworking 
• Communication with 
collaborators 
• Assessment of 
symptoms 
• Basic hygiene 
precautions* 
• Ventilation of the rooms 
Portugal University of 
Coimbra 





• All ongoing studies 
suspended 
 • Conduction of online 
experiments later 
implemented in the 
lab’s work 
• Implementation of 
teleworking 
• PPE 
Russia National Medical 
Research Center 








• All ongoing studies 
suspended 
• Interruption of data 
collection 
• Data loss from ongoing 
studies 
• Implementation of 
teleworking 
• To be decided 






June 8, 2020 







• All ongoing studies 
and in-person 
activities suspended 
• Interruption of data 
collection 
• Data loss from ongoing 
studies 
• Psychological effects of 
COVID-19 might 
influence the data 
 
• Implementation of 
teleworking 
• Basic hygiene 
precautions* 
• Remote data collection 
if possible 
• Scheduling office use 
• Measuring the 
temperature of 
participants 
• Ventilation of rooms 
• Switch to a round coil if 
possible 












• All ongoing studies 
suspended 
• Interruption of data 
collection 
• Decreased testing 
capacity due to safety 
precautions 
• Fewer healthy 
participants 
• Lower statistical power 
for studies terminated 
earlier 
• Implementation of 
teleworking 
• New lab routines to 
keep staff motivated 
• Analysis of data from 
nearly complete 
studies 
• Basic hygiene 
precautions* 
• Remote data collection 
if possible 
• Scheduling office use 
• Monitoring the infection 
of staff members 











March 9, 2020 To be decided, 
maybe January 
2021 
• Interruption of ongoing 
research 
• Contacting patients is 
not allowed for remote 
research purposes 
• Illness of staff members 
(COVID-19 was not 
confirmed but 
symptoms were similar) 
• Support for junior lab 
members who live alone 
• Implementation of 
teleworking 
• New lab routines to 
keep staff motivated 
• Collecting follow-up 
data remotely 
• Participation to online 
workshops 
• PPE 
• Home-based tDCS 
• Shift schedules for staff 
members 








To be decided • Interruption of ongoing 
research (clinical and 
preclinical) 
• Interruption of data 
collection 
• Implementation of 
teleworking 
• Conducting modelling 
and in silico studies 
• To be decided 






June 1, 2020 
• All ongoing studies 
and in-person 
activities suspended 
• Data loss from ongoing 
studies 
• Interruption of data 
collection and recently 
commenced studies 
• Drop-out of subjects 
with interrupted protocol 
• Delayed completion of 
multisite clinical trials 
• Need to recruit new 
subjects when restarting 
the studies 
• Implementation of 
teleworking 
• Single-use sponges and 
head fixture devices for 
tES 
• Basic hygiene 
precautions* 
• Training for staff and 
students 
• Testing for COVID-19 
• PPE for staff and 
participants 








May 18, 2020 •  All ongoing studies 
and in-person 
activities suspended 
• Data loss from ongoing 
studies 
• Interruption of data 
collection 
• Implementation of 
teleworking 
• Questionnaire or 
checklist to assess 
COVID-19 risk 
• Testing for COVID-19 
• PPE 
• Remote or home 
stimulation 
NY, USA NYU Langone 






• Interruption of all 
outpatient visits 
outside of standard 
care or justified risk 
 
• Redeployed research 
staff to work remotely 
• Continued all ongoing 




• Received IRB approval 




research program with 
home-based remotely 
supervised tDCS 







• PPE  
• Shift schedules for staff 
members 
• Social distancing 
measures 















In Process, TBD 
• All studies considered 
‘non-essential 
operations’ on 
immediate hold, which 
placed infant and child 
stroke studies on hold 
• Data loss from studies 




• Loss of participants with 
interrupted protocol, 
infants will now likely 
age out of the study 
dependent upon safety 
and date of 
reimplementation 
• Delayed completion of 
clinical trials 
• Continuous monitoring 
of inpatient pediatric 
census for return to 
research and new 
recruitment 
• Research staff/trainees 
established for secure 
at-home access and 
productivity 
• Secured IRB approval 
for two COVID-19 




a Family Impact to 
Rehabilitation Access 
On-Line Survey 




in the pediatric 
population 
• PPE  
• Shift schedules for 
staff/trainees  




and infant positioning 
for neuromodulation 
• Continue tele-research 
program with home-
based remotely 




• Testing for COVID-19 
as per University 
protocols  
• PPE for staff /trainees 
and participants 
tDCS: transcranial direct current stimulation; TMS: transcranial magnetic stimulation; tES: transcranial electrical stimulation; PPE: personal protective 
equipment. 
basic hygiene precautions*: PPE, sanitization, social distancing 
Table 3. Summary of Considerations for COVID-19 Response. 
Initial 
• Cessation of non-essential in-person research activities 
o Followed by determination of compatibility with continuation through valid remote 
assessment and/or intervention methods 
• Movement of study teams to remote work to adhere with stay-at-home mandates 
o Special consideration required for remote access to resources (hardware, software, 
etc.) 
• Potential continuation of patient studies defined as essential care (e.g., depression), 
institution-specific determination 
• Allow reduced numbers of study team members to remain at work to continue essential study 
activities (e.g. shift or staggered working patterns) 
• Communication with all participants currently enrolled in ongoing studies to provide 
information regarding how their participation in the study will be impacted by any stay-at-
home mandates.  
o As applicable, communication to participants around any potential risk of COVID-19 
transmission in relation to ongoing participation. 
• Provide participants with additional information regarding available local resources (e.g. 
telemental health services, community assistance programs, etc.) 
• Training specific staff or consider additional personnel resources for coordinating COVID-19 
safety procedures 
During 
• Continue remote/teleworking activities such as analyzing data, manuscript writing, grant 
preparation, virtual meetings, adverse event follow-up, etc. 
• Plan for study procedure changes to maximize participant safety and social/physical 
distancing (e.g., PPE and other safety procedures, facility and equipment disinfection) 
• Plan for possible re-integration strategies (tiered, split, etc.) and how the team will adjust to 
accommodate institutional strategies 
• Prioritize study activities that will occur in person once stay-at-home mandates are lifted to 
account for overburden of study teams due to prior missed visits, upcoming follow-up 
assessments, and need for new participants to replace those with interrupted and 
unrecoverable intervention schedules. 
• Consider revision of ongoing studies to minimize person-to-person contacts through 
remote/online/teleassessment for questionnaires, self-report measures and other items not 
requiring in-person administration 
• Consider necessary redesign of study space to minimize participant contact time during 
intervention delivery 
• Further evaluation of feasibility for movement to remote assessment and intervention 
administration as a precaution for future COVID-19 related stay-at-home mandates. 
• Consider procedures for implementation of rapid COVID-19 testing and antibody assays 
noting and depending on any limitations in current testing and antibody assays regarding 
sensitivity, specificity or established relevance to risk. 
• Explore e-consenting procedures and e-questionnaires etc. 
Future 
• Consult reputable sources (IRB, CDC, FDA, etc.) for guidance on the timeline for study 
restart.  
• Devise a mitigation plan to limit exposure to Covid-19 or any other infectious agent for study 
subject/participant as well as research staff 
• Immediate implementation of planned procedures and updated safety precautions (i.e. 
standard operating procedure documents), with appropriate staff training. 
• If appropriate procedures for participant/patient safety (PPE, facility design, etc.) and other 
required procedures are implemented following the first wave of COVID-19, consider how the 
implementation of rapid COVID-19 testing and antibody assays may allow for the 
continuation of appropriate in-person activities that were immediately discontinued in the 
initial emergency response to the first COVID-19 outbreak. This decision will be institution 
specific. 
• Consider creating a financial plan involving possible sources and a calculation on the costs in 
case of subsequent outbreaks (e.g. the acquisition of all necessary equipment) 
 
Highlights 
• We developed a framework for balancing the importance of NIBS operations with 
safety considerations, which facilitates the re-establishment of access to NIBS 
clinical services and research operations during COVID-19. 
• The present consensus paper provides guidelines and good practices for 
managing and reopening NIBS clinics and laboratories through the immediate 
and ongoing stages of COVID‑19. 
• The proposed robust and structured strategy aims to address the current and 
anticipated future challenges while maintaining scientific rigor and managing risk. 
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